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“In adult centers the nerve paths are something fixed, 
ended, immutable. Everything may die, nothing may be 
regenerated. It is for the science of the future to change, if 
possible, this harsh decree.” 
S. Ramon y Cajal 
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ABSTRACT 
Cell cycle regulators are expressed in neurons but they carry out non-cell cycle functions involving 
maturation, migration and synapse regulation. Neurons are nevertheless reported to re-enter the 
cell cycle in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease 
(PD). Neuronal cell cycle re-entry is also well established in in vivo and in vitro rodent models. 
However, cell cycle re-entry is usually associated to cell death instead of cell division. Thus, it is 
largely believed the cell cycle machinery of neurons is not fully functional, which is generally 
considered to be a consequence of their postmitotic status. Notwithstanding, we lack proof that 
the cell cycle machinery of neurons is dysfunctional nor whether its regulation is different from that 
of mitotic cells. The objective of the present work is to test the extent to which neurons can progress 
through the cell cycle and whether neurons and mitotic cells share the regulation of the cell cycle. 
To do so, cell cycle re-entry in mature primary hippocampal neurons was induced by Cyclin E-Cdk2 
fusion products. The fusion products induce cell cycle re-entry, cell cycle deregulation and, as in 
mitotic cells, this results in apoptosis instead of cell division. Howbeit, abrogation of checkpoint 
signaling in S, G2 or M-phases enables primary neurons to progress through the cell cycle. Neurons 
can readily enter M-phase and a subset of neurons undergoes cell division. Moreover, neurons 
adapt their differentiated biology to the cell cycle. In M-phase they lose the integrity of the axon 
initial segment (AIS), which is necessary to integrate synaptic input and generate action potentials 
as well as for neuronal viability. After prematurely exiting M-phase without undergoing cell division 
neurons recover the AIS. In conclusion, neurons and mitotic cells share G1, S, G2 and M-phase 
regulation and are capable of undergoing cell division.  
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RESUMEN 
Las neuronas expresan reguladores de ciclo de forma fisiológica. Éstos llevan a cabo funciones “no 
de ciclo” que incluyen maduración, migración y regulación sináptica. Sin embargo, se ha 
evidenciado que las neuronas pueden entrar en el ciclo celular en el curso de enfermedades 
neurodegenerativas como la enfermedad de Alzheimer y el Parkinson. La entrada en ciclo en 
neuronas también está ampliamente descrita en modelos roedores in vivo e in vitro. La entrada en 
ciclo en neuronas no está asociada a la división, sino a la muerte neuronal. Así, está ampliamente 
aceptado que la maquinaria de ciclo de las neuronas no es plenamente funcional, lo que 
generalmente se considera una consecuencia del estado postmitotic de la neurona.   A pesar de 
ello, no está demostrado que la maquinaria de ciclo neuronal sea disfuncional ni si la regulación de 
dicha maquinaria es distinta a la de células mitóticas. El objetivo del presente trabajo es determinar 
hasta qué punto las neuronas pueden progresar por el ciclo celular y si comparten la regulación del 
ciclo celular con células mitóticas. Para ello, se ha inducido la entrada en ciclo en neuronas primarias 
de hipocampo maduras usando proteínas de fusión basadas en Ciclina E y Cdk2. Estas proteínas de 
fusión inducen la entrada en el ciclo celular y su desregulación e, igual que en células mitóticas, esto 
lleva a la apoptosis en lugar de la división. Empero, la supresión de puntos de control del ciclo celular 
en las fases S, G2 y M permite el progreso del ciclo celular en las neuronas. Esta manipulación 
permite entrar en fase M a las neuronas y un subgrupo de ellas puede llegar a dividirse. Es más, las 
neuronas adaptan su biología diferenciada al ciclo. Durante la fase M éstas pierden la integridad 
del segmento inicial del axón (SIA), que es necesario para generar potenciales de acción y la 
viabilidad neuronal. Tras salir prematuramente de la fase M sin dividirse recuperan el SIA. En 
conclusión, las neuronas comparten con células mitóticas la regulación de la maquinaria de G1, S, 
G2 y M y pueden llegar a dividirse. 
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1. Introduction 
1.1. The mitotic cell cycle 
1.1.1. The cell cycle in brief 
The cell cycle consists of G1, S, G2, and M-phases. Mitotic cells can undergo continuous cycles that 
entail the progression through G1/S/G2/M directly into another G1/S/G2/M cycle. Alternatively, 
cells can complete a cell cycle and withdraw from it into quiescence (G0). Quiescence is a reversible 
withdrawal from the cell cycle and is routinely induced in culture models by serum starvation, loss 
of adhesion or contact-inhibition [1]. Quiescent cells can physiologically re-enter the cell cycle when 
the appropriate conditions are met. Senescence is another form of cell cycle withdrawal, albeit it is 
permanent instead of reversible [2]. Senescent cells cannot be physiologically induced to re-enter 
the cell cycle. Unlike quiescence, senescence in response to cell cycle deregulation can be elicited 
at any phase of the cell cycle [2–4]. However, senescence is not part of the cell cycle machinery per 
se and is induced after cell cycle arrest and exit. Accordingly, senescence can also be induced in 
quiescent cells [5].  
G1 is the first growth phase and gates S-phase entry. During early G1, growth factors and integrin 
signaling regulate progression up to R [6]. Once R requirements are met, G1 progression becomes 
growth factor-independent. However, additional G1 progression is regulated by nutrient availability 
[6]. Origin licensing is completed at the end of G1, which is the formation of pre-RC that will be 
activated in S-phase to synthesize DNA [7]. Origins are licensed only once per cycle, which prevents 
DNA re-replication. During S and G2, centrosomes are also duplicated and will nucleate 
microtubules to form the mitotic spindle in M-phase [8]. Again, centrosome duplication only takes 
place once per cycle. G1/S/G2 phases are collectively known as interphase (but will also include G0 
hereafter). G2 is followed by M-phase, during which karyokinesis (nuclear division) and cytokinesis 
(cytoplasm division) take place. M-phase (mitosis proper) is subdivided into prophase, 
prometaphase, metaphase, anaphase, and telophase. Prophase sees the beginning of chromatin 
condensation, centrosomes polarize and early mitotic spindles are formed. NEB takes place during 
prometaphase, allowing the k-fibers of the mitotic spindle to attach to the chromosome 
kinetochores [9]. During metaphase, push-pull forces, as well as the release and re-attachment of 
k-fibers to the kinetochores, results in chromosome alignment at the spindle equator [10]. At this 
point, sister chromatids are bi-oriented to each centrosome. In anaphase, sister chromatids are 
pulled apart in preparation for telophase.  During telophase, chromatin de-condenses and the NER 
takes place, engulfing the chromatin into two new nuclei [9]. Cytokinesis entails the specification 
of the cleavage plane by the central spindle, actomyosin ring formation at the equatorial cortex and 
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its primary constriction during furrow ingression [11]. This results in the formation of an 
intercellular bridge that links the nascent daughter cells, wherein the central spindle forms the 
midbody. Adjacent to the midbody, an actomyosin-independent secondary constriction takes 
place. This resulting in abscission of the daughter cells, namely cell division.  
Not all physiological cell cycles entail the sequential passage through G1/S/G2/M phases. Mitotic 
cells can undergo a cell cycle that does not include cell division, which result in polyploid cells with 
multiples of the diploid chromosome content (multiples of 2N) [12]. In endoreplication (also termed 
endocycle), cells undergo cycles consisting of G1/S/G2 but not M-phase. Since endoreplication 
cycles do not involve karyokinesis, the resulting are cells with single nuclei with a ploidy of 4N or 
more. In contrast, endomitotic cycles entail the entry into M-phase without cytokinesis. These 
cycles may or may not entail karyokinesis. In cases in which they do, endomitosis results in cells 
with multiple nuclei and a ploidy of 4N or more. Not all endoreplication and endomitotic cycles 
(collectively referred to as endocycles hereafter) result in multiples of the diploid content (4N, 8N, 
16N, etc.), as some preclude the replication of specific genes. In such cases, endocycles result in 
increased DNA content that is not a multiple of the diploid content [12] (e.g. 3C). Aneuploidy refers 
to entire chromosome loss/gain (e.g. 3N) frequently associated with CIN during carcinogenesis [13]. 
However, aneuploidy is often used to refer to loss/gain of DNA regardless of ploidy.    
In summary, mitotic cells can undergo proliferative cell cycles consistent of G1/S/G2/M (continuous 
cycle) (Fig. 1a) or G0/G1/S/G2/M (re-entry from quiescence) (Fig. 1b), and endocycles consistent of 
G1/S (endoreplication) (Fig. 1c) or G1/S/M-phases (endomitosis) without cytokinesis (Fig. 1d). In 
diploid cells, physiological cycle with cytokinesis results in new diploid cells, whilst endoreplication 
or endomitosis in tetraploid/polyploid cells. Endomitosis can entail single nucleus or 
multinucleation, depending on whether karyokinesis has taken place.  
Figure 1. Cell cycle programs. a Continuous cell cycle consistent of G1/S/G2/M. b Cell cycle with 
exit into quiescence (G0). c and d Endocycles. Cell cycles without intervening M-phase result in 
endoreplication (c) and with M-phase entry but without cell division result in endomitosis (d). 
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1.1.2. The cell cycle in detail 
In the classical model, the cell cycle is regulated by cyclins and Cdks [14]. Cyclins oscillate during the 
cell cycle and activate specific Cdks, which are largely stably expressed. Hence, the oscillatory 
expression of cyclins drives the cyclic phases of the cell cycle. At initial stages of G1, extracellular 
signals regulate the transcription, translation, and stability of Cyclin D1/2/3 isoforms (Fig. 2a). These 
signals involve growth factors [15] and integrin signaling [16]. Cyclin D isoforms bind and activate 
Cdk4/6. In turn, CycD-Cdk4/6 phosphorylate the pocket proteins Rb, p107 (also known as RBL1) and 
p130 (also known as RBL2) (Fig. 2b). To do so, CykD-Cdk4/6 have to overcome negative regulation 
exerted by the INK4 family, which comprises p16 (also known as INK4A or CDKN2A), p15 (also 
known as INK4B or CDKN2B), p18  (also known as INK4C or CDKN2C) and p19 (also known as 
INK4D or CDKN2D, and p14 in mice) [17]. Rb family phosphorylation by CycD-Cdk4/6 relieves Rb 
repression over E2F family transcription factors. Of the E2F family, E2F1/2/3 are associated with 
transcriptional activation of the G1/S program and are repressed by Rb [18]. E2F4 and E2F5 are 
transcriptional repressors of E2F target genes and depend on Rb family proteins to exert their 
effects. Regulation of E2F6/7/8 is Rb family-independent and suppress the E2F G1/S transcriptional 
program at G2 [18]. Rb suppression of E2F1 is the most studied in G1/S regulation. Cyclin E1/2 
isoforms are key transcriptional products of E2F1, which drive late G1 progression, transition into 
S-phase and S-phase progression [19] (Fig. 2c). Cyclin E isoforms bind and activate Cdk2 and further 
phosphorylate Rb (Fig. 2d), forming a positive feedback loop with E2F1 that drives the 
transcriptional program of S-phase (Fig. 2e). CycE-Cdk2 complexes are inhibited by the CIP and KIP 
family, which comprises p21 (also known as Cip1 or CDKN1A, hereafter p21), p27 (also known 
as Kip1 or CDKN1B, hereafter p21) and p57 (also known as Kip2 or CDKN1C, hereafter p57) [20]. 
Cdk2 inhibitors p21 and p27 also bind CycD-Cdk4 but result in their stabilization and facilitation 
of nuclear shuttling instead of inhibition. CycD-Cdk4/6 titrate the inhibitors away from CycE-
Cdk2, therein facilitating the activation of the latter holoenzyme [17]. Conversely, INK4 family 
inhibitors can displace p27/p21 from CycD-Cdk4/6, therein redirecting p27/p21 to CycE-Cdk2 
[17]. CycE-Cdk2 positive regulation of E2F3, but not E2F1, also drives Cyclin A2 expression, which 
is necessary for S-phase progression [21]. There are two Cyclin A isoforms. Cyclin A1 is essential 
for spermatogenesis, whilst Cyclin A2 is the somatic isoform [22]. As Cyclin E, Cyclin A1/2 
isoforms bind and activate Cdk2 to drive S-phase but, unlike Cyclin E, also Cdk1 to drive M-phase 
entry. As opposed to CycE-Cdk2, CycA-Cdk2 negatively regulates E2F1, which terminates its 
transcriptional program [22].  
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Figure 2. Rb-E2F1 program. Cyclin 
D1/2 levels accumulate during early 
G1 and, once p16/p15/p19 
inhibition is overcome, activate 
Cdk4/6 (a). CycD-Cdk4/6 
phosphorylates the Rb (b) and 
relieves Rb-dependent suppression 
over E2F1 transcription factor. E2F1 
positively regulates the G1/S 
transcriptional program (c), among 
which a key target is Cyclin E. Cyclin 
E1/2 levels accumulate during late 
G1 and, once p27/p21/p57 
inhibition is overcome, activate 
Cdk2 (d). CycE-Cdk2 feeds back into 
the negative regulation of Rb (e), 
which further de-represses E2F1 
and iterates the positive regulation 
of Cyclin E, driving G1/S transition. 
 
CycE/A-Cdk2 are further involved in origin licensing in G1 and origin firing in S-phase, events that 
are necessary for DNA synthesis [23] (Fig. 3). Origin licensing entails the assembly of pre-RC on 
origins [7]. This requires the sequential loading of ORC and Cdc6 onto the chromatin (Fig. 3a). CycE-
Cdk2 phosphorylates Cdc6, which prevents its degradation by the APC/C [24]. Loading of ORC and 
Cdc6 enables the recruitment of Cdt1 and MCM2-7 proteins, all of which are E2F products [25–29]. 
In cells re-entering G1 from G0, Cyclin E is necessary to load MCM proteins [30,31]. MCM2-7 form 
a head-to-head double hexamer (DH), which is the core of the replicative helicase that will unwind 
DNA [7]. Origins are licensed once the DH is formed (Fig. 3a). Hence, Cyclin E is involved in the 
positive regulation of the E2F1 G1/S transcriptional program by inhibiting Rb proteins but also in 
the assembly of DNA replication machinery. Once licensed, CycA-Cdk2 phosphorylation of Cdc6 
results in its release from the pre-RC [32] and geminin sequesters Cdt1 away from the pre-RC [33], 
collectively preventing re-licensing and re-replication (Fig. 3b). Cdt1 is also degraded by the Skp2 
[34]. Next, the MCM2-7 helicase is phosphorylated by DDK, which is composed of Cdc7 protein 
kinase and the regulatory subunit Dbf4 [7]. CycA-Cdk2 activity enables the recruitment of the 
complex formed by Sld5 and Psf1-3 (GINS, meaning go-ichi-ni-san in Japanese, 5-1-2-3 after 
Sld5/Psf1-3) [7]. Coordinated actions of Cdk2 and DDK afford the formation of the Cdc45/MCM2-
7/GINS (CMG) complex, the replicative helicase [7] (Fig. 3c). This destabilizes the DH, resulting in 
each of the hexamers extruding a ssDNA and the unwinding of the dsDNA (Fig. 3d) and origin firing. 
Requiring MCM10, RPA loads onto the ssDNA, which enables further loading of DNA polymerases 
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and DNA synthesis. The amount of firing origins is below the amount of licensed origins [7,35]. The 
licensed origins that do not fire are termed dormant origins. 
Figure 3. Origin licensing and firing. a The assembly of the pre-RC marks the sites at which origins are 
licensed to fire. Cdc6 binds ORC starting at late M-phase, followed by Cdt1 and subsequently by MCM 2-
7 proteins. The origin is licensed for replication when two head-to-dead MCM2-7 hexamers form an DH, 
which has no active helicase activity. b Cdc6 and Cdt1 are released from the pre-RC and cannot license 
new origins within the ongoing cell cycle, which prevents re-replication. c DDK and Cdk2 activity leads to 
the loading of Cdc45 and GINS onto MCM2-7 in S-phase, forming the CMG complex. d During helicase 
activation, the DH separate and extrude one ssDNA each (origin firing) enabling DNA replication.  
 
Another event that begins in S-phase is centrosome duplication. Centrosomes are the MOC that 
give rise to the k-fibers, astral and polar microtubules of the mitotic spindle [8]. The centrosomes 
are composed by two orthogonal centrioles surrounded by PCM, which is involved in nucleating 
and organizing the cytoplasmic microtubules. Normally, there is one centrosome in a cell in G0/G1. 
In G1, a daughter and mother centriole are loosely held together by a proteinaceous linker [8]. The 
mother centriole can be identified by its appendages, which are absent in the daughter centriole 
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[8]. During the G1/S transition, Plk4 recruitment and activity at the centrioles prompts the 
nucleation of procentriolar microtubules. The new centrioles elongate the proximal region during 
S-phase and the distal region during G2-phase. The daughter and mother centrioles, with a new 
centriole each, become disengaged by the severing of the proteinaceous linker at the G2/M 
transition. Centrosome maturates during late G2 and M-phase, which entails Aurora-A sustained 
activation of Plk1 and the recruitment of PCM proteins to each of the two new pairs of centrioles. 
Increased PCM stimulates centrosome microtubule nucleation. Kinesin motor protein Eg5 binds 
antiparallel microtubules and drives the centrosomes to opposite sides of the nucleus to form the 
bipolar spindles. K-fibers of the mitotic spindle attach to the chromosome kinetochores, driving 
chromosome congression until metaphase.  
The key event driving G2/M transition is the activation of CycB1-Cdk1 [36,37] (Fig. 4). CycB1-
Cdk1 results in a mitotic phosphorylation program that is opposed by PP2A and PP1 [38]. Beyond 
DNA synthesis, CycA-Cdk2 is at least partially responsible for driving the accumulation of active 
CycB-Cdk1 complexes in G2 (Fig. 4a). The Cyclin B family is composed of isoforms B1/B2/B3. Cyclin 
B isoforms are expressed shortly after Cyclin A [36]. E2F1/2/3 positively regulate Cyclin B1, whilst 
E2F4 is a negative regulator [39]. Other positive regulators of Cyclin B1 are MYBL2 (also known as 
B-MYB) NF-Y and FoxM1 [36] (Fig. 4b). CycA-Cdk2 is a positive regulator of CycB1 transcription 
factors, including E2F, MYBL2, NF-Y, and FoxM1, which results in a build-up of Cyclin B1 in S and G2 
[36]. The activity of CycB1-Cdk1 is negatively regulated by Wee1 family kinases Wee1 and Myt1 
(Fig. 4c) and positively regulated by Cdc25 phosphatases [37] (Fig. 4d). Increase of Cyclin B1 levels 
eventually overcome Cdk1 inhibition by Wee1/Myt1. Once active, CycB1-Cdk1 inhibits Wee1/Myt1 
(Fig. 4e) and activates Cdc25 phosphatases (Fig. 4f), which results in a positive amplification loop 
that drives M-phase entry. In Drosophila and Xenopus egg extracts M-phase entry also involves 
CycB1-Cdk1-dependent activation the greatwall kinase, which ultimately suppresses PP2A-
regulatory subunit B55 (PP2A-B55) [38]. However, activation of the mammalian GW homolog 
MASTL does not appear to be mandatory for G2/M transition [37]. Nevertheless, okadaic acid, the 
potent phosphatase inhibitor that targets PP1 and PP2A among others, triggers M-phase entry in 
mammalian cells. Altogether, the progressive accumulation of Cyclin B1 eventually results in a 
positive amplification loop that results in a switch-like activation of the mitotic program leading to 
chromosome condensation, NEB and the formation of the mitotic spindle.   
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Figure 4. CycB-Cdk1 regulation of G2/M 
transition. CycA-Cdk2 drives the 
expression of CycB1, which accumulates 
during G2 (a). Cyclin B1 binds Cdk1 (b), 
but Cdk1 activation requires the relief 
from Wee1/Myt1-dependent inhibition 
(c) and Cdc25 phosphatases-dependent 
activation (d). In turn, CycB1-Cdk1 
negatively regulates Wee1/Myt1 (e) and 
positively regulates Cdc25 phosphatases 
(f), resulting in a switch-like activation of 
the mitotic phosphorylation program 
when sufficient levels of Cyclin B1 are 
reached. 
 
CycB1-Cdk1 complexes remain active until metaphase but have to be inactivated in order to elicit 
anaphase and subsequent telophase (Fig. 5). The levels of Cyclin B1 are maintained high from 
prophase to metaphase by the SAC [40] (Fig. 5a). From prometaphase to metaphase the SAC 
monitors correct sister kinetochore biorientation to achieve chromosome alignment, wherein sister 
kinetochores are to be properly attached to kinetochore fibers nucleated from centrosomes at 
opposite poles [40]. Respectively, attachments are stabilized and destabilized by antagonistic 
actions of PP2A-B56 and Aurora B until the correct bi-orientation of sister chromatids is reached 
[10]. Before bi-orientation, SAC activation exerts pre-anaphase arrest by sequestering Cdc20 to the 
centromeres, away from APC/C [40]. This prevents APC/CCdc20 targeting of Cyclin B1 and securin for 
destruction (Fig. 5b), events required to trigger anaphase [41]. Once proper bi-orientation is 
achieved, APC/CCdc20 is activated. Securin degradation enables the proteolytic activity of separase, 
which hydrolyzes the centromeric cohesin complexes holding the sister chromatids together. 
Mitotic spindle K-fibers shorten, pulling the now free sister chromatids towards each spindle pole. 
APC/CCdc20 targeting of Cyclin B1 for destruction results in inactivation of Cdk1, which is central to 
reverse mitotic phosphorylation and elicit anaphase and cytokinesis onset [11,38,42].  
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Figure 5. Cyclin B1 and APC/C in M-phase. a The SAC prevents the degradation of Cyclin B1 and 
securin until proper chromosome alignment is reached in metaphase. This is achieved by 
sequestering Cdc20 away from the APC. b Upon correct chromosome alignment, the SAC is 
satisfied, Cdc20 sequestration is relieved and APCCdc20 targets Cyclin B1 and securin for destruction, 
which results in anaphase/cytokinesis onset. Loss of CycB1-Cdk1 activity enables APCCdh1 activity, 
broadening the destruction program of APC for mitotic exit. This includes the degradation of Cdc20 
and other regulators such as Aurora B. APCCdh1 continues active in G1, where it negatively regulates 
G1 progression.  
 
The onset of cytokinesis takes place during anaphase with the assembly of the central spindle (also 
known as the spindle midzone), which is formed by stabilized antiparallel microtubule bundles 
midway between the spindle poles. The central spindle takes part in positioning the plane of 
division [11] (but also see [43]). This depends on PRC1, CPC  [42] and the centralspindlin complex 
[44], composed of Rho family GTPase activating protein Cyk4 and Mklp1 [11]. The CPC is formed by 
Aurora B together with surviving, INCENP and borealin [42]. Loss of CycB1-Cdk1 activity enables the 
dimerization of PRC1, which crosslinks none k-fiber antiparallel microtubules and stabilizes the 
central spindle (Fig. 5b), and affords the binding of the CPC subunit INCENP to Mklp2, which results 
in CPC-Mklp2 targeting from the centromeres to the central spindle. The CPC subunit Aurora B 
phosphorylates the Mklp1 subunit of centralspindlin, which increases complex oligomerization, 
clustering of the complex and bundling of microtubules. Further, Plk1 phosphorylates Cyk4 of the 
centralspindlin complex, which permits the docking of ECT2. Through ECT2, centralspindlin at the 
central spindle and the equatorial cortex induces the localized activation of RhoA small GTPase. 
RhoA activity elicits the assembly of the actomyosin ring at the equatorial cortex and its constriction 
by inducing formin-dependent actin nucleation and ROCK activation of myosin II. ROCK also 
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indirectly activates myosin II by inhibiting MYPT. The actomyosin ring is attached to the plasma 
membrane, wherein its constriction at the equatorial cortex narrows the cytoplasmic connections 
between the daughter cells (furrow ingression). Furrow ingression results in the formation of an 
intercellular bridge that, at the central region, derives from the central spindle dense antiparallel 
microtubule bundles (midbody or Flemming body). Adjacent to the midbody, abscission is 
completed by a secondary actin and myosin independent ingression. For abscission to take place, 
actin and microtubules have to be disassembled and ESCRT-III has to be targeted to the abscission 
site, once Plk1 is degraded by the APC/C [11,45].  
Plk1 is an APC/CCdh1 substrate [46] (Fig. 5c). As mentioned, APC/CCdc20 targeting of Cyclin B1 and 
securin for destruction is necessary for anaphase/cytokinesis onset [41] (Fig. 5b). Cdh1 co-activation 
of APC/C substitutes APC/CCdc20 activity at late mitosis, broadening the substrate specificity of APC/C 
to induce mitotic exit (Fig. 5c). Whilst CycB1-Cdk1 primes co-activation of APC/C by Cdc20, it inhibits 
co-activation by Cdh1. Hence, CycB1 degradation mediated by APC/CCdc20 enables APC/CCdh1 
activation. Targets of APC/CCdh1 are Cdc20 itself but also Aurora kinases and Plk1. APC/CCdh1 
continues active in G0 and G1, where it counteracts cell cycle re-entry by targeting substrates such 
as Cdc6, which is necessary for origin licensing, and Skp2 [41], which directs SCF targeting of p27 
and p21 for degradation during G1 progression [47] (Fig. 5c). 
1.1.3. Cell cycle restriction points and checkpoints 
Mitotic cells have to overcome R as an initial commitment to undergo the cell cycle [6] (Fig. 6a). In 
addition to R, S-phase entry has been proposed to be gated by a nutrient sensing checkpoint 
dependent on mTOR (Fig. 6b). This latter checkpoint, a “growth checkpoint”, would ensure nutrient 
sufficiency to enable the cell growth required to produce two daughter cells. Collectively, 
extracellular signals and nutrient availability regulate the levels of G1 cyclins, Cdks inhibitors and 
their nucleocytoplasmic shuttling.  
Cell cycle checkpoints are different from the R and growth checkpoints. They are activated in 
response to stressors such as DNA damage and ensure progression through G1, S, G2, and M-phases 
are correct. DNA damage sensitive checkpoints are mainly regulated ATM and ATR signaling [48,49], 
essential upstream regulators of the DDR. ATM chiefly responds to DSB whilst ATR to ssDNA 
stretches.  
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Figure 6. Cell cycle checkpoints and premature cell cycle exit. a The R monitors sufficient growth 
factor availability. b Once R is overcome, G1 progression is growth factor-independent but further 
progression still requires nutrient availability and is mTOR-dependent. c G1/S transition is gated by 
the ATM/Chk2 dependent G1 checkpoint. d Stretches of ssDNA activate the intra-S checkpoint and 
is ATR/Chk1-dependent. e DNA damage within G2 elicits the ATM/Chck2-dependent G2 checkpoint. 
f The ATR/Chk1-dependent S-M checkpoint is activated by slow DNA replication during S-phase. g 
The antephase checkpoint responds to stressors other than DNA damage. h The decatenation 
checkpoint arrests cells at the G2/M transition when centromere arms are not sufficiently 
decatenated. i The SAC monitors the correct chromosome bi-orientation and arrests cells in 
metaphase. j The abscission checkpoint is Aurora B-dependent and is activated by the presence of 
chromatin in the intercellular bridge. k Mitotic skipping is a form of premature cell cycle exit from 
G2.  l Mitotic slippage is activated by prolonged SAC activation and results in cell cycle exit prior to 
anaphase.    
 
The G1 checkpoint prevents entry into S-phase in response to DNA damage and is largely associated 
to ATM signaling [48] (Fig. 6c). ATM activates Chk2. ATM and Chk2 stabilize the tumor suppressor 
protein p53, enabling its transcriptional program. Within this program, upregulation of p21 results 
in Cdk2 inhibition and cell cycle arrest [48]. In addition, p53 also positively regulates Fbw7, which 
forms part of the SCFFbw7 complex that targets Cyclin E for degradation [50]. Further, ATM/Chk2 
signaling has been reported to result in Cdc25A degradation and a block on DNA replication [51].  
The intra-S checkpoint relies on ATR signaling and its downstream kinase Chk1 [49] (Fig. 6d). ATR 
signals through Chk1 to inhibit Cdc25A and, consequently, Cdk2/1, therein effecting a p53/p21-
independent cell cycle arrest. Noteworthy, Chk1 also inhibits Cdc25B and C. The intra-S checkpoint 
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is activated in every cell cycle [49]. DNA unwinding during normal S-phase results in ssDNA that are 
coated by RPA, which engages ATR signaling. However, during RS, slowed and or stalled replication 
forks result in the uncoupling of the helicase from DNA polymerase. This results in longer stretches 
of RPA coated ssDNA and heightened intra-S checkpoint signaling. This response is necessary to 
prevent fork collapse, which in turn enables the re-initiation of elongation after checkpoint silencing 
[49]. However, if forks collapse they cannot terminate processing the region of DNA associated to 
the active origin (replicon). As mentioned, it is not possible to re-license origins to finish the 
processing of the replicon [7]. Instead, replicon processing is finished after fork collapse by Chk1-
dependent activation of dormant origins in active replication factories [35]. Replication factories 
are sequentially activated to replicate different chromosomal domains throughout S-phase. The 
intra-S checkpoint allows the activation of dormant origins within an active replication factory 
whilst blocking the activation of new replication factories [49]. Otherwise, early and late 
chromosomal domains would be processed simultaneously and lead to excess origin firing and 
increased of RS rather than its reduction.  
Gathering the above, the G1 checkpoint signaling by ATM/Chk2 responds to DNA DSB, enables DSB 
repair and exerts cell cycle arrest via p52/p21 [48]. The intra-S checkpoint responds to ssDNA, 
prevents fork collapse, inhibits origin firing in new replication factories, activates dormant origins 
in active replication factories and exerts cell cycle arrest by inhibiting Cdc25A [49]. However, ATM 
and ATR activation cannot be unambiguously excised. Fork collapse after sustained fork stalling 
results in DNA DSB, which recruit ATM in addition to ATR [48,49]. Conversely, as part of DSB repair 
involving ATM, strand resection during recombination pathways in S-phase generates ssDNA, RPA 
coating and in turn ATR signaling. Thus, DDR signaling by ATM/ATR is usually concomitant.  
Once in G2-phase, the activation of CycB1-Cdk1 is targeted by checkpoints to prevent M-phase 
entry with DNA damage or defective DNA replication [52]. As in G1 and S-phase, distinct G2 
checkpoint signaling networks depend on ATM and ATR. Acute arrest in G2 in response to DNA 
damage within G2 is thought to require ATM/Chk2 [52] (Fig. 6e). In contrast, impaired DNA 
synthesis in S-phase results in delayed albeit prolonged arrest in G2 effected by the S-M checkpoint, 
which is dependent on ATR and independent of ATM [52] (Fig. 6f). The ATR-dependent intra-S and 
S-M checkpoints are complementary, yet have different consequences on the cell cycle machinery. 
The intra-S checkpoint ensures faithful S-phase progression whilst the S-M checkpoint prevents 
premature M-phase onset. [48,49,52]. To arrest the cell cycle, the intra-S checkpoint targets Cdk2 
whilst the S-M checkpoint targets Cdk1. The latter is achieved by ATR/Chk1 inhibitory 
phosphorylation of Cdc25A/C phosphatases and the activation of Wee1/Myt1. Thus, the intra-S and 
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S-M checkpoints do not entail different signaling pathways per se, yet the relevant targets are 
different as a function of the stage of the cell cycle in which they are activated.  
There are additional checkpoints in G2 that do not respond exclusively to DNA damage. The 
antephase checkpoint operates in late G2 and early M-phase, wherein prophasic cells can be 
reverted to interphase [53] (Fig. 6g). It is dependent on CHFR and p38. Also preventing G2/M 
transition, the decatenation checkpoint is activated when TOP2α has not sufficiently decatenated 
dsSCI between the sister chromatid chromosome arms [54] (Fig. 6h). The decatenation checkpoint 
signaling itself requires decatenase-independent scaffolding functions of TOP2α [55].  
Within M-phase, cell cycle progression from prometaphase to metaphase is monitored by the SAC 
[40] (Fig. 6i). SAC activation depends on Mps1 kinase activity, which targets Mad2 to the 
kinetochores [56–61]. In turn, Mad2 sequesters Cdc20 to the kinetochores and prevents APC/CCdc20 
mediated destruction of Cyclin B1 and securin. This prevents anaphase. After anaphase onset, 
cytokinesis failure can be a checkpoint-independent event and lead to physiological or pathological 
aneuploidy, tetraploidy or polyploidy [62]. In addition, stretches of chromatin linking the separating 
nuclei (chromosome bridges) during cytokinesis trigger the Aurora B-dependent abscission 
checkpoint [45] (Fig. 6j). In mammals, chromatin bridges physically prevent abscission. The 
abscission checkpoint itself blocks furrow regression by stabilizing the attachments between the 
midbody and the plasma membrane. Hence, the checkpoint affords the time to resolve chromatin 
bridges, favoring cytokinesis completion in lieu of tetraploidization.  
1.1.4. Cell death and senescence 
Cell cycle checkpoints ensure the completion of physiological cell cycle. Notwithstanding, if cell 
cycle deregulation is not amended, additional signaling is executed to elicit oncosuppressive fates 
that involve either cell death or senescence. Cell cycle related cell death can be p53-dependent and 
independent in response to E2F1 activation [63]. In principle, this form of cell death can be executed 
during phases in which E2F1 drives the cell cycle, mainly G1 and S-phases but could also be possible 
in G2. Senescence and cell death are p53-dependent in response to DNA damage during S-phase 
[3]. However, this does not involve E2F1 but instead, ATM/Chk2 activation. Alternatively, 
senescence can be induced after cell cycle exit from G2, which is known as mitotic skipping and also 
appears to require p53 and inactivation of CycB1-Cdk1 signaling [64–66] (Fig. 6k). It stands to reason 
that mitotic skipping is dependent on ATM/Chk2 checkpoint signaling, but this remains 
undetermined.  
As mentioned, the G2 and S-M checkpoint prevent M-phase entry of cells bearing unresolved DNA 
damage and or aberrant DNA structures [52]. Failure to amend DNA damage prior to M-phase can 
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result in mitotic catastrophe [4]. Mitotic catastrophe is an oncosuppressive mechanism that can 
preclude M-phase completion by triggering apoptosis, necrosis or senescence. Hence, it is a 
compendium of events rather than a single mechanism. In addition to DNA damage [67], 
centrosome amplification can also have catastrophic consequences in M-phase (e.g. multipolar 
cytokinesis) [68]. Noteworthy, prolonged checkpoint-dependent G2 arrest to amend DNA damage 
can result in centrosome amplification. Hence, indirectly, G2/S-M checkpoint signaling itself can 
cause mitotic catastrophe as well as prevent it.  Once in M-phase, prolonged SAC activation can 
lead to pre-anaphase cell death or mitotic slippage [69] (Fig. 6l). Mitotic slippage entails cell cycle 
exit without cell division (and is different from SAC adaptation, which does not take place in 
mammals). It appears that whether cell death or mitotic slippage takes place in M-phase is 
determined by the levels of Cyclin B1 degradation, were reaching a low threshold of Cyclin B1 elicits 
mitotic slippage and an upper threshold cell death within M-phase.  
 
1.2. The neuronal cell cycle 
1.2.1. The postmitotic status of neurons 
The traditionally perspective of the postmitotic status of neurons is that it entailed a unique form 
of permanent cell cycle withdrawal. Most cells in the adult are withdrawn from the cell cycle. Rather 
than in a postmitotic state comparable to neurons, mitotic cells in the adult are quiescent or 
senescent. Quiescent cells re-enter the cell cycle upon physiological stimulation [1]. While it has 
been evidenced that immature neurons can re-enter the cell cycle when exposed to non-
physiological calcium stimulation [70], cell cycle withdrawal in neurons is not physiologically 
reversible. Thus, neurons are unlike quiescent cells. In contrast, there is evidence to suggest 
neurons can become senescent [71–77]. Howbeit, neurons are already withdrawn from the cell 
cycle prior to showing any signs of senescence. Hence, postmitotic cell cycle withdrawal in neurons 
is unlike senescence. Finally, while there is proliferation in the central nervous system during adult 
neurogenesis, proliferative activity takes place in NSC [78]. Once NSC differentiate into neurons, 
they are not reported to proliferate.  
Gathering the above, neurons are in a unique postmitotic state that is not shared with proliferating 
cells during development or in adulthood. Nevertheless, the molecular correlates of the postmitotic 
status of neurons remain obscure. Retinal precursor cells [79,80] and cortical neuroblasts [81] but 
also retinal horizontal interneurons [82] and cortical neurons [83] have been shown to re-enter the 
cell cycle and proliferate in vivo in KO models of Rb family proteins. M-phase markers were also 
reported in neurons in KO models of p27 and p19 [84], which prevent the inhibition of Rb family 
28 
 
function. Thus, Rb signaling may be underlay the postmitotic status of neurons. However, Rb 
signaling is essential to cell cycle withdrawal in mitotic cells, making it highly unlikely that it is a 
determinant of neuron-specific cell cycle withdrawal. Further, germline Rb KO models in non-
neuronal cells result in differentiated phenotypes that are not comparable to acute KO in WT cells, 
which have undergone normal differentiation [85]. Hence, the proliferative capacity of neurons in 
the aforementioned KO models can alternatively reflect lack of differentiation. Along these lines, 
while immature neurons can undergo cell division [70,86,87], cell cycle re-entry in mature neurons 
results in cell death [70]. Moreover, when proliferation has been reported in mature neurons, it has 
been reported after dedifferentiation [88], in which case cell cycle activity is no longer taking place 
in neurons. Of note, in chimeric Rb deficient mice, neurons are claimed to differentiate normally 
[89]. Howbeit, whilst neuronal differentiation in E13.5 chimeric embryos was assessed by MAP2 
immunostaining, when the differentiation phenotype of adult mice was assessed only 
morphological criteria was used to determine neuronal identity [89], which is unreliable. Further, 
at least Purkinje neurons were reported abnormal. When differentiation markers have been 
assessed to identify neuronal identity, Rb KO neurons do not appear to reach full maturation 
[90,91].  
It is well established that in the course of neuron diseases such as AD neurons can undergo cell 
cycle re-entry [92,93]. In contrast with neuronal proliferation in the above mentioned KO models, 
neuronal cell cycle re-entry  in neuron diseases is not followed by cell division but, instead, is 
associated with immediate or delayed cell death [92,93]. This limited cell cycle progression is 
congruent with evidence showing that the postmitotic limitations of neurons are acquired with 
maturation [70]. Cell death instead of cell division has led to argue that neurons are destined to die 
upon cell cycle re-entry [94–96]. This is largely supported by model systems. Cell cycle related cell 
death is triggered by NGF deprivation in primary sympathetic neurons [97–100] and cortical 
neurons [100], trophic factor deprivation in mice cerebellar granule cells in vivo [101], potassium 
withdrawal in primary cerebellar granule cells [102–107], oxidative stress in primary cortical 
neurons [108,109], DNA damage in rat primary cortical neurons [110], p27 siRNA in primary cortical 
neurons [111], oxygen glucose deprivation in primary cortical neurons and in vivo by transient 
middle cerebral artery occlusion [112], HIV-induced neurotoxicity in primary rat neuroglial cultures 
[113], miRNA-26b in primary rat neurons [114], calcium bath in primary neuron cultures [70], SV40 
LTAg in murine cerebellar cells in vivo [115–118], allele loss of Rb in vivo [119,120], excitotoxic 
glutamate in primary cortical neurons [121], excitotoxic kaininc acid alone in cerebellar granule cell 
cultures [122,123] or in combination with Parkin deficiency in primary cortical, midbrain and 
cerebellar neurons [124], in vivo intraperitoneal administration of kaininc acid [109], Aβ in primary 
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neurons [125–130], in vivo intracerebroventricular administration of Aβ [131],  prion peptides in 
primary cortical neurons [129], Parkinsonian mimetics MPP+ in cerebellar granule cell cultures 
[132,133] and MPTP in midbrain primary cultures [134], ischemia/hypoxia and toxic concentrations 
of hydrogen peroxide [108,121,122,125,128,132] to name but a few. Despite the evidence provided 
by model systems, there are limitations to cell cycle related cell death as a determinant of the cell 
cycle limitations of postmitotic neurons. Neurons that undergo re-entry in patients with AD do not 
immediately die even though they do not undergo cell division [93,135]. As opposed to cell death 
being mandatory upon re-entry, reports in AD rise the likely possibility that most model systems 
simply cannot model viable cell cycle re-entry.  
The postmitotic status of neurons was traditionally defined as an irreversible withdrawal from the 
cell cycle [93]. In the contemporary definition, the postmitotic status is defined by limitations 
imposed on the cell cycle after aberrant re-entry [93–96]. Said limitation appear to require normal 
differentiation and full maturation to be developed [70]. Whether involving cell cycle withdrawal 
or limitations on cell cycle progression after aberrant cell cycle re-entry, the molecular 
determinants of the postmitotic status remain unidentified in normally differentiated mature 
neurons.  
1.2.2. The mitotic status of neurons 
Whilst neuron-specific cell cycle regulatory mechanisms are the main focus in most studies, the 
standard cell cycle regulatory mechanisms of mitotic cells remain largely unexplored in neurons. 
The present work directly compares the cell cycle regulation and function of neurons with what is 
known in mitotic cells.  
Deregulated Cyclin E induces known alterations on the cell cycle machinery of mitotic cells [19]. 
Overactivation of Cyclin E results in the deregulation of DNA replication machinery [136–140], 
centrosome amplification [141], and defects in M-phase leading to chromosome bridges, 
multinucleation and micronucleation [142–145]. Thus, if neurons respond as mitotic cells, Cyclin E-
induced neuronal cell cycle re-entry can be used to predict checkpoint activation and the stage at 
which neurons would arrest the cell cycle. In turn, this will also provide the signaling cascades that 
should be targeted to devise checkpoint abrogation strategies that can enable cell cycle progression 
and, ultimately, neuronal cell division.  
In neurons, Cyclin E  binds to Cdk5 [146], inhibiting its kinase functions in synapse regulation [147] 
and excitability [148]. In turn, deregulated Cdk5 activity is widely reported in neurodegeneration 
[149]. Thus, to avoid confounding effects involving Cdk5, Cyclin E and Cdk2 based fusion proteins 
were generated. The fusion product should also avert monomeric Cyclin E degradation, which is 
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Cul-3-dependent [150]. Although full-length Cyclin E was also used, a fusion product based on the 
LMW Cyclin E isoform Cyclin ET1, which lacks the first 39 amino acids of Cyclin E [151], was used for 
most of the studies. LMW Cyclin E isoforms have been reported to result from the proteolytic 
cleavage of Cyclin E by the serine protease elastase [151,152] and the calcium-dependent cysteine 
protease calpain [152,153]. Calpain-dependent processing of Cyclin E into LMW isoforms has been 
reported in primary the cerebellar granule cells [132]. These isoforms have heightened oncogenic 
potential when compared to Cyclin E [154]. LMW isoforms hyperactivate Cdk2, are resistant to 
inhibition by p21 and p27 as well as SCFFbw7 dependent degradation [155–162]. Hence, Cyclin E/ET1 
and Cdk2 were used to form the EK2 and t1EK2 fusion products, respectively, and drive neuronal 
cell cycle re-entry. This was combined with checkpoint abrogation to study the extent to which 
neurons could progress through the cell cycle.  
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2. Objectives 
The main objective of this thesis is to study the functionality of the cell cycle machinery of 
neurons and the extent to which the neurons and standard mitotic cells share the regulation of 
the cell cycle.  
The specific objectives are to determine whether: 
1. t1EK2 and EK2 induce DNA synthesis in neurons. 
2. Checkpoint signaling results in cell cycle arrest and or cell death 
3. Checkpoint signaling abrogation prevents cell death and enables cell cycle progression 
through S, G2, and M-phases. 
4. Neurons adapt their physiology to accommodate the cell cycle. 
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3. Materials and Methods 
3.1. Plasmids  
pcDNA3-t1EK2 was based on pcDNA3-EK2 [163]. We substituted the sequence encoding Cyclin E 
(XP_006723520.1) and Cdk2 ISO2 (NP_439892.2) in EK2 for Cyclin ET1 and Cdk2 ISO1 (NP_001784). 
The cDNA for Cyclin ET1 encoded a sequence that lacked the first 40aa of Cyclin EL (NP_0012291) 
N-terminal domain. The cDNA encoding t1EK2 was synthesized into a pUC57 cloning vector by 
Genescript. t1EK2 was subsequently subcloned into the HindIII and XbaI sites of pcDNA3-D1K2, and 
sequence verified (Annex 1). pcDNA3- D1K2 was a kind gift from Brian K. Law. To generate an EK2 
fusion protein with Cdk2 ISO1 instead of Cdk2 ISO2 in EK2 [163], we subcloned Cyclin E 
(XP_006723520.1) from Rc/CMV Cyclin E (Addgene plasmid #8963) into the EcoRI and AgeI sites of 
t1EK2-pcDNA3 (Annex 2) and sequenced verified it. Rc/CMV Cyclin E (Addgene plasmid #8963) was 
a gift from Bob Winberg. t1EK2 and EK2 were both based on Cyclin E (XP_006723520.1) and Cdk2 
ISO 1 (NP_001784). The pcDNA6/V5-His/lacZ vector expressing LacZ was purchased from 
Invitrogen. The pRFPRNAiC vector expressing RFP, provided by Stuart Wilson (University of 
Sheffield, UK), has been previously described [164]. The pEGFP-N1 (GenNBank #U55762.1) vector 
expressing enhanced GFP was obtained from Clontech. The T7-p53DD-pcDNA3 vector expressing a 
dominant negative form of p53 [166] was a gift from William Kaelin (Addgene plasmid # 25989). 
The Histone H2 tagged with GFP (H2B-GFP) vector expressing a Histone-GFP fusion protein [167] 
was a kind gift from Geoff Wahl (Addgene plasmid #11680). The TOP2α-WT pcDNA3.1(+) vector 
expressing TOP2IIα [168] was a kind gift from Corrado Santocanale (National University of Ireland).  
3.2. Antibodies 
Primary antibodies: The anti-MAP2 chicken antibody ab5392 (Abcam) was diluted 1:12000. The 
anti-BrdU rat monoclonal antibody (mAb) [BU1/75 (ICR1)] (AbDSerotec) was diluted at 1:200. The 
cleaved Caspase-3 rabbit antibody (Cell Signaling Technology) was diluted at 1:400. The anti-pH3 
rabbit polyclonal antibody 06-570 (Millipore) was diluted at 1:500. The anti-γ-H2AX mouse 
monoclonal antibody [9F3] ab26350 (Abcam) was diluted at 1:500. The anti-anillin rabbit polyclonal 
antibody ab154337 (Abcam) was diluted at 1:100. The anti-α-tubulin mouse monoclonal antibody 
[DM1A] ab2791 (Abcam) was diluted at 1:5000-1:10000. The anti-AnkG mouse antibody [N106/36] 
(NeuroMab) was diluted at 1:150. Secondary antibodies: Alexa Fluor 488 Goat Anti-Rat IgG (H+L) 
(Life Technologies), Alexa Fluor 488 Goat Anti-Mouse IgG (H+L) (Life Technologies), Alexa Fluor 488 
Goat anti-Mouse IgG2a A-21131 (Invitrogen), Alexa Fluor 488 Affinipure Goat Anti-Rabbit IgG (H+L) 
(Jackson Immunoresearch), Alexa Fluor 594 Goat Anti-Rabbit IgG (H+L) (Life Technologies), and 
Alexa Flour 647 Goat Anti-Chicken IgY (H+L) A-21449 (Invitrogen) were used at 1:1000 dilution. 
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3.3. Inhibitory compounds 
Cdk1 inhibitor RO3306 (ref. 1530) was used at 9 µM, the Wee1 inhibitor MK1775 (ref. 1494) was 
used at 900 nM, and the Mps1 inhibitor AZ3146 (ref. 1642) was used at 10 µM and were purchased 
from Axon Medchem. The Eg5 inhibitor monastrol (ab14087) was used at 100 µM, and the 
proteasome inhibitor MG132 (ab141003) was used at 10µM and were purchased from Abcam. 
Caffeine (Sigma), used at 3 mM, was diluted in Neurobasal without L-Glutamine (ThermoFisher 
Scientific) and filter sterilized with 0.2 μm syringe filters (Acrodisc) freshly each day. 
3.4. Hippocampal cultures 
10-mm diameter coverslips (Menzel Glässer) were placed in 65% nitric acid (Merck) overnight. 
Coverslips were then washed 4 times with Milli-Q water (Millipore), once in pure ethanol (Merck) 
and air-dried. Coverslips were sterilized overnight in an oven at 185ºC, placed in CELLSTAR cell 
culture dishes with 4 inner rings (Greiner bio-one) and UV sterilized for 1 h. Coverslips were coated 
with 0.5 mg/ml PLO (Sigma-Aldrich) (prepared in 150 mM borate buffer, pH8.4) for at least 24 h. 
PLO was washed twice in sterilized Milli-Q water. CELLSTAR culture dishes were left in a humidified 
atmosphere containing 5 % CO2 at 37°C with 2ml of neuronal plating medium consistent of DMEM 
with D-Glucose, L-Glutamine and Pyruvate (ThermoFisher Scientific) containing 10 % FBS (Life 
Technologies) and penicillin-streptomycin (25 U/ml) (Gibco). Primary hippocampal neurons derived 
from CD-1 mice (Charles River) were harvested from embryonic day 17, staged as previously 
described [170]. Pups were decapitated and brains were placed in cold HBSS without calcium 
chloride, magnesium chloride, nor magnesium sulfate (Gibco). Hippocampi were then dissected and 
incubated for 15 min at 37ºC in 5 ml HBSS containing 2.5 mg/ml trypsin (Gibco) in a 15 ml conical 
centrifuge tube. 1 mg/ml DNAse (Roche) was added for the last 30 s. Hippocampi were then washed 
5 times in 5 ml of HBSS at 37ºC each time. Mechanical dissociation followed in 1ml of HBSS at 37ºC 
by passing hippocampi through a Pasteur pipette 10-15 times. Non-dissociated tissue was allowed 
to collect at the bottom by gravity and clean supernatant with dissociated cells transferred to a new 
15 ml centrifuge tube. 1 ml of HBSS at 37ºC was added to the remaining tissue and dissociated again 
with a flame polished Pasteur pipette to reduce the diameter of the tip 10-15 times. Non-
dissociated tissue was allowed to collect at the bottom by gravity. Clean supernatant with 
dissociated cells was transferred to the same centrifuge tube in which cells from the first 
dissociation were collected. Neurons were transferred at a density of 24.000 cells/cm2 to CELLSTAR 
cell culture dishes (Greiner bio-one) with neuronal plating medium. Neurons were allowed to attach 
to coverslips for 3 to 4 h in a humidified atmosphere containing 5 % CO2 at 37°C. Once neurons 
were settled onto the coverslips, neuronal plating medium was washed with maintenance medium 
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consistent of Neurobasal without L-Glutamine (ThermoFisher Scientific) medium supplemented 
with B27 (ThermoFisher Scientific), penicillin-streptomycin (25 U/ml) (Gibco) and GlutaMAX (Gibco) 
and differentiated with the same medium up to 3-4 DIV. Half of the culture medium was exchanged 
by fresh maintenance medium without penicillin-streptomycin every 3-4 days.  
3.5. Lipofection 
Neurons were transfected with Lipofectamine 2000 (Invitrogen). To increase neuron viability and 
efficiency of transfection, neurons were lipofected in their own culture dishes in their conditioned 
medium and recovered from lipofection also in their conditioned medium. As described above, 
neurons had been grown without penicillin-streptomycin from 3 DIV. Fresh maintenance medium 
was added every 3-4 days, also as described above. Two or three days prior to lipofection, half of 
the maintenance medium was changed for fresh medium. This ensured that the day of lipofection 
coincided with the next scheduled change of maintenance medium. The day of lipofection, each 
cell-culture dish was numbered. 30-60 min prior to lipofection, half of the conditioned medium of 
each neuronal culture (1 ml) was removed and collected into a clean culture dish identified with 
the same number. Number identification was used to avoid cross-contamination. 1 ml of fresh 
maintenance medium was added to each culture dish containing medium, which were used to 
provide the recovery medium after lipofection. Dishes containing recovery medium were incubated 
in a humidified atmosphere containing 5 % CO2 at 37°C for the duration of the lipofection. BrdU (5 
µg/ml) and or inhibitors were added to the recovery medium as needed. In preparation for 
lipofection, 0.5 ml of Neurobasal medium without supplements pre-warmed to 37°C was added to 
each of the neuronal cultures. At this point, each culture contained 1ml of conditioned medium 
plus 0.5 ml of Neurobasal without supplements.  Cultures were returned to the incubator for a 
minimum of 30 min to stabilize CO2 levels. RFP/GFP DNA was always transfected at a 1:20 ratio to 
total transfected DNA. Multiple Lipofectamine to DNA ratios were tested during initial studies. For 
the rest of the experiments, lipoplexes were prepared at a ratio of 1 μl of Lipofectamine per 1 μg 
of DNA. For immunocytochemistry experiments, total transfected DNA per culture dish for 
t1EK2/RFP and LacZ/RFP experiments was 6.4 μg and total transfected DNA per culture dish for 
t1EK2/p53DN/RFP, LacZ/p53DN/RFP, t1EK2/p53DN/TOP2α/RFP, LacZ/p53DN/TOP2α-RFP 
experiments was 12.85 μg. For time-lapse experiments, total transfected DNA for 
t1EK2/p53DN/H2B-EGFP was 10.27 μg and for t1EK2/p53DN/TOP2α/H2B-EGFP it was 12.44 μg. 
Lipofectamine was gently mixed with Neurobasal to a final volume of 250 μl per culture dish and 
left for 3-5 min, maximum. Next, plasmid DNA diluted in 250μl of Neurobasal per culture dish was 
added and left for 20 min at room temperature. Thereafter, 0.5 ml of the mix was gently added 
drop by drop to each culture dish and left for 90-120 min, maximum. Lipofectamine was then gently 
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washed out 3 times with 2 ml of fresh maintenance medium pre-warmed to 37ºC. After washout, 
the recovery medium was added to its corresponding neuronal culture. For cytokinesis 
experiments, cultures were supplemented with 1xEmbryoMax Nucleosides (Merck) [138]. 
3.6. Cell cycle protocols 
Protocol to assess late G2 and M-phase. At 1.5 dtp, the proteasome was inhibited with MG132 
(10µM) to prevent mitotic exit [171] and the accompanying loss of pH3 staining [172]. Neurons 
were fixed for immunocytochemistry 4 h later. Protocol to assess G2/M phase transition after 
Wee1 inhibition. At 1.5 dtp, the proteasome was inhibited with MG132 (10µM) to prevent mitotic 
exit [171] and the accompanying loss of pH3 staining [172]. One hour later, MK1775  (900 nM) was 
added to inhibit Wee1 and abrogate S-M checkpoint signaling [173]. Neurons were fixed for 
immunocytochemistry 4 h after addition of MG132 (10µM). Protocol for G2 synchronization and 
release. The day of transfection, neurons were treated with the Cdk1 inhibitor R03306 [174] (9 µM) 
to synchronize neurons in G2. Synchronization in G2 was used to prevent M-phase entry of neurons 
that could otherwise progress into M-phase without activating the G2/S-M checkpoints. This was 
done because these neurons were likely to have reduced levels of DNA damage [52], which can 
facilitate M-phase completion [67]. RO3306 (9 µM) was used to synchronize neurons for cytokinesis 
induction experiments at longer dpt time-frames (2 dpt). Neurons could not undergo mitotic 
skipping form G2 because it depends on p53 [64–66] and they were expressing the p53DN, nor 
mitotic slippage from M-phase because they were arrested at G2 by RO3306 (9 µM). Caffeine (3 
mM) was added at 2 dpt to inhibit ATM/ATR [175] before RO3306 (9 µM) washout to prime G2/M 
transition. Two and a half hour later RO3306/Caffeine were washed and Caffeine (3 mM) was added 
again to sustain G2 checkpoint abrogation. Protocol for prometaphase synchronization and 
release. Neurons were treated with the motor kinesin Eg5 inhibitor monastrol [176] (100 µM) to 
synchronize neurons in prometaphase. At shorter dpt intervals monastrol (100 µM) was preferred 
over RO3306 (9 µM) because it enabled the visual identification of neurons that progressed into M-
phase. Monastrol prevents centrosome separation and results in monoastral spindles, which result 
in a rosette-like organization of the chromatin that can be identified in EGFP-H2B positive 
chromatin. Thus, these cells can be identified for time-lapse experiments whereas G2 arrested cells 
cannot.  As noted, these cells were targeted because they likely entered M-phase without activating 
the G2/S-M checkpoints. In consequence, they were likely to have reduced levels of DNA damage 
[52], which can facilitate M-phase completion [67]. However, at longer dpt neurons arrested in M-
phase by monastrol (100 µM) could undergo mitotic slippage. At 1 dpt, monastrol (100 µM) was 
washed and caffeine (3 mM) was added to induce M-phase entry of neurons that were arrested by 
the G2 checkpoint. Protocol for anaphase synchronization. The G2/M transition was induced with 
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caffeine (3 mM). AZ3146 [58] (10 µM) was added 2.5 h later to abrogate de SAC and induce 
anaphase/cytokinesis. Neurons were fixed for immunocytochemistry 30 min. latter. 
3.7. Immunocytochemistry 
Hippocampal cultures were fixed for 15 min with 4 % paraformaldehyde (PFA) at RT and 
permeabilized for 30 min with PBTx. For BrdU immunolabelling, DNA was denatured for 30 min at 
RT with 2N HCl/0.33× PBS, and then neutralized with three 15-min washes with 0.1 M sodium 
borate, pH 8.9, and a wash of 5 min with PBTx. Cultures were then incubated for 30 min at room 
temperature with PBTx containing 10 % FBS to block antibody unspecific binding, followed by a 1-
h incubation at RT with PBTx/1 % FBS and the appropriate primary antibodies. After 4 washes in 
PBTx, cultures were incubated for 1 h at RT in PBTx containing 1 % FBS and the appropriate 
secondary antibodies. After 4 additional washes as above, DNA labeling was performed using PBS 
containing 100 ng/ml DAPI (Sigma-Aldrich) and the preparations were mounted in glycerol 
(Panreac)/PBS (1:1). 
3.8. Image analysis and cell counting studies 
Cell counting in BrdU, active Caspase-3, pH3, and γ-H2AX experiments was done with 20x (Zoom, 
1.5) or 40x objectives with AF 6500-7000 fluorescence microscope (Leica) and a DU8285 VP-4324 
camera (Andor). Confocal microscope images were acquired with 40x or 63x objectives using 
upright or inverted TCS SP5 confocal microscopes (Leica). For three-dimensional (3D) image 
reconstructions, images were taken with a 63x objective with 1.7- to 3.6-times zoom, in 50 to 69 z-
stacks of 0.13 to 0.25 µm step-sizes. 3D reconstructions and rotating 3D videos were generated 
using Icy bioimage informatics platform [177]. S-phase. For BrdU incorporation time-course 
experiments, the proportion of BrdU positive neurons out of all MAP2 positive transfected neurons 
of 10-mm diameter coverslips (MenzelGlässer) was calculated in 3 independent experiments. Late 
G2 and M-phase. pH3 immunostaining was used to assess late G2 and M-phase entry [172], 
wherein the proportion of neurons positive for foci (late G2) or pan-nuclear (M-phase) staining out 
of all MAP2 positive transfected neurons was calculated in each of 3 independent experiments in 
each treatment condition. Apoptosis. The proportion of active caspase-3 [178] positive neurons of 
all MAP2 positive transfected neurons was calculated in each of 3 independent experiments. DNA 
Damage. DNA damage was assessed with γ-H2AX [179]. The proportion of neurons with more than 
5 γ-H2AX foci or γ-H2AX pan-nuclear staining out of all MAP2 positive transfected neurons was 
calculated in each of 3 independent experiments. AIS. AnkG was used to evaluate changes in the 
AIS of neurons at different stages of the cell cycle. All groups were treated with Wee1 inhibitor 
MK1775 (900 nM) to abrogate the G2 checkpoint and with the Mps1 inhibitor AZ3146 (10 µM) 2.5 
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h later to abrogate the SAC. Neurons in the interphase, prophase, and prometaphase to telophase 
groups were fixed 3 h after G2 checkpoint abrogation. Stages in between prometaphase and 
telophase could not be reliably distinguished by nuclear morphology and were thus grouped 
together. Multinucleated neurons were used to assess premature M-phase exit and were fixed 6 
and 9 h after G2 checkpoint abrogation. Multinucleated neurons still presenting mitotic chromatin 
condensation or evidence of pyknosis were not included in the quantification. Neurons in all of the 
aforementioned groups co-expressed t1EK2/p53DN/TOP2α/RFP. Control neurons expressing 
LacZ/p53DN/TOP2α/RFP were fixed 9 h after G2 checkpoint abrogation. Images were acquired on 
an upright Leica SP5 confocal microscope with a 63× objective, 1024 × 1024 pixels in z stacks with 
0.5-μm steps and a Z-projection was obtained. Measurements of AnkG fluorescence intensity were 
performed by Fiji-ImageJ software. A line starting at the limit of neuronal soma identified by MAP2 
staining and extended it along the AnkG staining or the RFP signal of the axon was drawn. Data was 
obtained after background subtraction. Then, data was smoothed every 1 μm using Sigma Plot 12.5 
software. AIS start and end positions were obtained following the criteria described previously 
[180]. Next, the total fluorescence intensity for each AIS was obtained. Total fluorescent intensity 
was divided by the length of the AIS to obtain the mean AnkG fluorescence per 1 µm (AnkG/µm). 
To avoid variability between cell cultures and treatment exposure times, the mean AnkG/µm of 
transfected neurons was normalized to the nearest neighboring non-transfected neurons in the 
same image.  
3.9. Live imaging 
Neurons were cultured as described above in µ-Dish 35mm, high Grid-500 cell culture dishes with 
Ibidi polymer coverslip bottom (Ibidi) coated with 0.5 mg/ml polyornithine (Sigma-Aldrich). Live 
neuronal imaging was performed in a sealed chamber at 37ºC and 5 % CO2 with the 20x objective 
of an AF 6500-7000 fluorescence microscope and recorded with the DU8285 VP-4324 camera. 
Pictures and videos were generated using Leica Application Suite X (Leica). For cell counting studies 
of anaphase and cytokinesis, neuronal identity was determined by morphological criteria based on 
RFP signal. When in doubt, cells were either not included in the quantification or neuronal identity 
confirmed by MAP2 immunostaining and included in the quantification. Neurons that presented 
obvious signs of cell death during the first hour of recording were not included in the quantification. 
Chromosome segregation during anaphase was identified by H2B-GFP [167] and cleavage furrow 
ingression by RFP.  
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3.10. Statistical analysis 
Statistical analysis was performed using SPSS (version 24.0). Statistical analysis of BrdU time-course 
experiments of pH3 experiments was done with one-sample t-test against 0 because control 
neurons never incorporated BrdU or were positive for pH3 (α=0.05, one-tailed). For BrdU time-
course experiments, the mean percent BrdU incorporation of the treatment group was compared 
to 0 in each time-point. Analysis of active-caspase-3 and γ-H2AX experiments were done with 
Fisher’s exact test (α=0.05, two-tailed). For AnkG/µm in AIS experiments, outliers were identified 
by box plots. Normality was assessed with the Shapiro-Wilk test of normality and Normal Q-Q Plots. 
Homogeneity of variances with Levene’s test for equality of variances. Omnibus testing was 
performed with Welch’s F test and post-hoc multiple comparisons with the Games-Howell method 
(α=0.05, two-tailed). Quantitative data are expressed as mean ± standard error of the mean 
(s.e.m.).  Significance was p<0.05 (*), p<0.01 (**), and p <0.001 (***). 
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4. Results 
4.1. t1EK2 and EK2 induce DNA synthesis in neurons. 
EK2, t1EK2 or control LacZ were co-lipofected with a vector expressing GFP in hippocampal cultures 
maintained for 6-9 DIV. Transfected neurons were identified by MAP2-specific labeling in GFP-
positive cells. BrdU incorporation was assessed 1, 2, and 3 dpt. One-way ANOVA and Games-Howell 
multiple comparisons were performed for each dpt separately. Transfected control neurons never 
incorporated BrdU (n=349) (Fig. 7a, b top row), indicating that neurons in primary culture between 
6-12 DIV do not spontaneously re-enter the cell cycle. Transfected contaminant cells, likely 
astrocytes and or microglia, were present in the cell cultures and, as expected, they did not stain 
positive for MAP2 (Fig. 7b bottom row). t1EK2 and EK2 induced DNA synthesis in neurons at 1 dpt 
(F2,360=118.873, p<0.001) and 2 dpt (F2,266=55.627, p<0.001) whilst at 3 dpt only t1EK2 expressing 
neurons showed BrdU incorporation (F2,181=63.493, p<0.001) (Fig. 7a, c, d).  Games-Howell multiple 
comparisons revealed that the proportion of t1EK2 expressing neurons incorporating BrdU at 1 dpt 
(74.68 %, p<0.001) and 3 dpt (47,62 %, p<0.001) was significantly higher than for EK2-expressing 
neurons at 1 (37.62 %) and 3 dpt (0.0 %) (Fig. 7a). At 2 dpt, the differences were not statistically 
significant between t1EK2 (52.9 %) and EK2 (35.2 %) expressing neurons (p=0.088) (Fig. 7a). The 
results showed that t1EK2 induced BrdU incorporation in a larger proportion of neurons at a faster 
rate than EK2. This is consistent with the higher oncogenic potential of LMW Cyclin E isoforms [154]. 
In both cases, BrdU incorporation reached its peak at 1 dpt and thereafter declined. BrdU was 
administered to the cultures on the day of transfection, so the loss of BrdU incorporation at 2 and 
3 dpt could only reflect the disappearance of neurons that were positive for BrdU at 1 dpt. At 2 and 
3 dpt deteriorating neurons were present both in EK2 (Fig. 7c at 3 dpt) and t1EK2 (Fig. 7d at 3 dpt) 
groups.  
Neurons expressing t1EK and EK2 presented an aberrant chromatin morphology. The chromatin 
was stretched into dendrites and axons (Fig. 7e, f) and or displaced from what appeared to be the 
soma (Fig. 7f). This phenotype was not necessarily concomitant to BrdU incorporation and 
appeared to be particularly pronounced in EK2-expressing neurons (Fig. 7f). Subsequent analysis of 
these aberrant nuclear phenotypes in the same group of neurons confirmed the differences 
between t1EK2 and EK2-expressing neurons (Fig. 7g). Control neurons never presented the 
aforementioned chromatin morphology (n=349) (Fig. 7g). EK2 expressing neurons presented 
aberrant chromatin at 1 (13.86 %), 2 (18.31 %) and 3 dpt (32 %) and this proportion was statistically 
significantly higher than for t1EK2 expressing neurons at 1 (3.16 %; p = 0.013), 2 (4,29 %; p = 0.023) 
and 3 (0.0 %: p = 0.007) dpt (1 dpt: F2,360=11.761, p<0.001; 2 dpt: F2,266=15.351, p<0.001; 3 dpt: 
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F2,181=36.802, p<0.001) (Fig. 7g). The aberrant chromatin phenotype remains unexplained. 
Nevertheless, the initial studies indicated t1EK2 is the optimal option to induce cell cycle re-entry 
in neurons. 
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Figure 7. t1EK2 and EK2 induce DNA synthesis in neurons. a-c Percentage of BrdU positive 
neurons expressing LacZ (Control), t1EK2 or EK2 at 1 (Control: n=104; t1EK2: n=158; EK2: n=101), 
2 (Control: n=128; t1EK2: n=70; EK2: n= 71), or 3 (Control: n=117; t1EK2: n=42; EK2: n=25) dpt (6-
9 DIV). Control neurons never incorporate BrdU. (***p<0.001; N.S. Non-significant; One-way 
ANOVA and Games-Howell multiple comparisons were performed each day). b Representative 
fluorescence microscope images of LacZ-transfected control neuron (top) and MAP2-negative cell 
(bottom, yellow arrows) at 1 dpt. c and d Representative fluorescence microscope images of EK2 
and t1EK2-transfected neurons at 1, 2 and 3 dpt. Nuclei location is indicated by white arrows. At 
3dpt aberrant nuclear and dendritic morphology indicative of cell death is common. Nuclei 
location of neurons is indicated by white arrows and BrdU positive MAP2-negative nuclei by 
yellow arrows. e, f Representative fluorescence microscope images of the aberrant chromatin 
phenotype found in t1EK2 (e) and EK2 (f) expressing neurons. Stretched chromatin and or bulk 
chromatin location is indicated by white arrows. Bottom panels of e are a magnification of DAPI 
and merged channels for better visualization of stretched chromatin. g Percentage of neurons in 
a presenting aberrantly stretched chromatin as stained by DAPI. Control neurons never present 
the aberrant phenotype (***p<0.001; **p<0.01; One-way ANOVA and Games-Howell multiple 
comparisons were performed each day). Graphs represent mean ± s.e.m. 
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4.2. t1EK2 induces DNA synthesis and neuronal cell death 
Cell cycle regulators are present in neurons where they are involved in non-cell cycle functions 
[147,181] and their expression levels vary with maturation [182–185]. In particular, Cyclin E levels 
increase during development whilst driving synapse maturation [147] until they stabilize at high 
levels in adults [147,183–187]. This cautions against performing further experiments in immature 
primary neuron cultures, as cell cycle re-entry is not likely to be regulated in the same way as in 
mature neurons. Hence, transfections were performed in hippocampal cultures maintained for 15 
DIV, a stage in which synapses are present [188]. BrdU incorporation was assessed at 1, 1.5 and 2 
dpt. It could not be assessed at 3 dpt due to widespread deterioration of t1EK2-expressing 
neurons, which could reflect the susceptibility of mature primary neurons to cell cycle re-entry. 
Control neurons were always negative for BrdU (n=491) (Fig. 8a, b). t1EK2 induced 52.3 % BrdU 
incorporation at 1 dpt (t152=12.906, p<0.001), 58.9 % at 1.5 dpt (t128=13.548, p<0.001) and 46.8 % 
at 2 dpt (t93=9.047, p<0.001) (Fig. 8a, b). As seen in the initial studies with 6-9 DIV neurons (Fig. 
7a), BrdU incorporation decreased at 2 dpt in 17 DIV neurons (Fig. 8a).   
 
Figure 8. t1EK2 induces DNA 
synthesis and neuronal cell 
death. a Percentage of BrdU 
positive neurons expressing 
LacZ (Control) or t1EK2 at 1 
(Control: n=129; t1EK2: 
n=153), 1.5 (Control: n=201; 
t1EK2: n=129), and 2 (Control: 
n=161; t1EK2: n=94) dpt (16-
17 DIV). Three independent 
experiments for each dpt were 
carried out. As control neurons 
never incorporated BrdU, 
statistical analysis was 
performed by comparing 
percent BrdU incorporation in 
t1EK2-expressing neurons 
with zero (***p<0.001; one-
tailed t-test for each dpt). b 
Representative confocal 
images of BrdU incorporation 
in a LacZ control neuron (1 dpt) 
and t1EK2-expressing neurons 
at 1, 1.5 and 2 dpt. Arrows 
identify RFP positive neurons. 
Graphs represent mean ± 
s.e.m. Scale bar: 25 µm.  
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4.3. t1EK2-induces cell cycle related apoptotic cell death 
Neuronal death upon cell cycle re-entry was expected because it is widely reported in the literature 
[92–96]. Cyclin E signaling, in particular, is associated with apoptotic neuronal cell death 
[104,108,114,121,122,124,125,128]. Thus, active caspase-3 immunolabelling was performed to 
assess apoptosis [178] at 1.5 dpt. At 1.5 dpt, 34.7% of t1EK2-expressing neurons were positive for 
active caspase-3 and this was statistically significantly higher than control neurons (6.0 %) at 1.5 
dpt (p<0.001, Fisher’s exact test) (Fig. 9a, b, c). Hence, at least a significant proportion of neurons 
were undergoing apoptotic cell death at 1.5. This was likely an underestimation, as neurons did not 
enter the cell cycle synchronously, and would therefore not be expected to die at the same time.  
 
Figure 9. t1EK2 induces cell cycle related apoptotic cell death. a Percentage of active caspase-3 
positive neurons expressing LacZ (n=150) or t1EK2 (n=150) at 1.5 dpt (17 DIV). Three independent 
experiments were carried out (***p<0.001; two-sided Fisher’s exact test). b, c Representative 
confocal images of active caspase-3 immunostaining in a LacZ control neuron (b) and a t1EK2 (c) 
expressing neuron. Note that the active caspase-3-positive nucleus is pyknotic (c). Arrows identify 
RFP positive neurons. Graphs represent mean ± s.e.m. Scale bar: 25 µm.  
 
4.4. p53 loss of function prevents t1EK2-induced apoptosis 
Neurons do not always immediately die upon re-entry in vivo [135,189,190], so cell cycle re-entry 
itself is not irreversibly catastrophic for neurons. In mitotic cells, oncogene-induced RS can elicit 
ATM/Chk2 checkpoint signaling that is conducive to p53-dependent oncosuppressive cell death 
[3,48]. Cyclin E is known to induce RS [136–139,191–195]. Specifically, overexpression of Cyclin E 
but not Cyclin D1 [196] or Cyclin A [197] results in genomic alterations associated with RS. Cyclin E 
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has been reported to induce RS by preventing origin licensing in continuously cyclin cells [193] but, 
paradoxically, also by depleting the nucleotide pools [138] and catalyzing the collision between 
replication and transcription machinery [137,140] due to excess and or premature origin firing. p53 
loss of function is known to facilitate carcinogenesis driven by deregulated Cyclin E 
[50,195,198,199] and LMW Cyclin E [142,154,200]. Hence, t1EK2 induced cell cycle related 
apoptosis in neurons could be caused by p53 signaling, as in mitotic cells. To assess this possibility, 
t1EK2 was co-expressed with a dominant negative mutant of p53, p53DN [166], and apoptosis was 
assessed again. The proportion of active caspase-3-positive t1EK2-p53DN-expressing neurons (6.0 
%) was not statistically significantly different from control neurons expressing p53DN (1.3 %) at 1.5 
dpt (p=0.061, Fisher’s exact test) (Fig. 10a-e). Overall, t1EK2-p53DN neurons presented normal 
nuclear morphology (Fig. 10c), which was consistent with rescue from apoptosis. However, neurons 
occasionally presented mitotic chromatin condensation consistent with M-phase entry (Fig. 10d, 
e).    
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Figure 10. p53 loss of function prevents t1EK2-induced apoptosis. a Percentage of active caspase-
3 positive neurons expressing LacZ-p53DN (n=150) or t1EK2-p53DN (n=150) at 1.5 dpt (17 DIV). 
Three independent experiments were carried out (p<0.05; two-sided Fisher’s exact test;). b, c 
Representative confocal images of active caspase-3-negative control LacZ-p53DN (b) and t1EK2-
p53DN (c) expressing neurons. d Fluorescence microscope images of active caspase-3-negative 
neuron apparently undergoing cytokinesis (top row) and a multinucleated neuron (bottom row). 
The chromatin bridge present during cytokinesis (top row neuron) can result in cytokinesis failure 
and multinucleation (bottom row neuron). e Confocal image of an active caspase-3-negative 
neuron presenting mitotic chromatin condensation characteristic of prophase with 3D 
reconstruction of the nucleus (DAPI). White arrows identify nuclei. Blue, red and green arrows 
represent 3D orientation. Graphs represent mean ± s.e.m. Scale bar: 25 µm.  
 
4.5. p53 loss of function rescues DNA synthesis 
To test whether BrdU incorporation was rescued by p53DN, a BrdU time course was carried out, 
albeit this time at 1, 2, and 3 dpt instead of 1, 1.5 and 2 dpt. Control neurons never incorporated 
BrdU (n=1,043) (Fig. 11a, b). t1EK2-p53DN-expressing neurons were positive for BrdU labelling at 1 
(38.8 %) (t375=15.429, p<0.001), 2 (61.2 %) (t293=21.509, p<0.001), and 3 dpt (61.8 %) (t203=18.109, 
p<0.001) (Fig. 11a, b). Hence, BrdU incorporation remained stable at 3 dpt after plateauing at 2 dpt. 
Further, neurons positive for BrdU could still be found at 5 dpt (Fig. 11c), at which point neurons 
had been cultured for 20 DIV.  
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Figure 11. p53 loss of function rescues DNA synthesis. a Percentage of BrdU positive neurons 
expressing LacZ-p53DN (Control) or t1EK2-p53DN at 1 (Control: n=325; t1EK2-p53DN: n=376), 2 
(Control: n=406; t1EK2-p53DN: n=294), and 3 (Control: n=312; t1EK2-p53DN: n=204) dpt (16-18 
DIV). Three independent experiments for each dpt were carried out. As control neurons never 
incorporated BrdU, statistical analysis was performed by comparing percent BrdU incorporation in 
t1EK2-p53DN-expressing neurons with zero (***p<0.001; one-tailed t-test for each dpt). b 
Representative confocal images of BrdU incorporation of a LacZ-p53DN control neuron (3 dpt) and 
t1EK2-p53DN-expressing neurons at 1, 2, and 3 dpt. c Confocal images showing BrdU incorporation 
in t1EK2-p53DN-expressing neurons at 5 dpt. Arrows identify RFP positive neuron nuclei and 
arrowheads RFP/MAP2-negative (non-neuronal) cells. Graphs represent mean ± s.e.m. Scale bar: 
25 µm. 
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4.6. Neuronal cell cycle progression is arrested in late G2 
As indicated, viable neurons that were negative for active caspase-3 could occasionally present 
nuclear morphology consistent with M-phase entry (Fig. 10d, e). However, most viable neurons 
remained with an interphase nuclear morphology (e.g. absence of mitotic chromatin 
condensation). The fate of viable neurons after cell cycle re-entry in AD is yet to be explained [93]. 
Neurons that survive re-entry without entering M-phase and undergoing cell division in AD patients 
have been proposed to be in an “undead” state [93], which has been described in Drosophila [201] 
but is reminiscence of senescence in mammals [202]. Hence, t1EK2-expressing neurons may be 
“undead”. Alternatively, t1EK2-expressing neurons may still remain within the cell cycle, between 
S and G2-phases, or have exited the cell cycle. The latter is unlikely because the exit from S-phase 
[3,136,203] and from G2 by mitotic skipping relies on p53 signaling [64–66] and neurons were 
expressing p53DN. In contrast, cells with p53-dysfunction have deficient G1 checkpoint signaling 
and are known to undergo S-M checkpoint-dependent arrest in G2 to repair DNA damage [52]. This 
is likely because p53 dysfunction impairs the expression of p21, which inhibits CycE-Cdk2 [198]. 
Thus, a purposely designed protocol (Fig. 12) was used to study whether neurons were in late G2 
and, further, confirm whether the occasional neurons presenting prophasic-like morphology (Fig. 
10d, e) were indeed in M-phase. Cells in late G2 can be identified by pH3 foci whereas neurons in 
M-phase by pan-nuclear pH3 staining [172].   
 
Figure 12. Protocol to assess late G2 and M-phase. Oncogenes induce G1/S transition (1) and RS 
that can lead to p53-dependent apoptosis [3]. In turn, the loss of function of p53 affords viability 
and cell cycle progression (2). However, p53 dysfunction impairs the ATM-dependent checkpoint 
program [52]. Thus, p53-deficient cells rely heavily on ATR-dependent G2 arrest to amend DNA 
damage prior to M-phase entry (3). Cells arrested at late G2 can be identified by pH3 foci staining 
of the nucleus and cells that have undergone G2/M transition by pan-nuclear pH3 staining [172]. 
However, the loss of pH3 staining begins at anaphase and ends in telophase. Alternatively, mitotic 
slippage can result in cell cycle exit and loss of pH3 prior to anaphase onset. Anaphase onset and 
mitotic slippage were blocked with the proteasome inhibitor MG132 (10µM) [171] to prevent the 
loss of pH3 signal in neurons that had entered M-phase during the duration of the experiment (4). 
This ensured that all neurons that entered M-phase during the experiment were detected.   
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Control MAP2-positive neurons were never positive for pH3 (n=150) (Fig. 13a, b). In contrast, 45.3 
% (t149=11.116, p<0.001) of t1EK2-p53DN-expressing neurons reached late G2 (Fig. 13a, c top row). 
In addition, 2.7 % (t149=2.020, p<0.05) of t1EK2-p53DN-expressing neurons progressed beyond G2 
into M-phase (Fig. 13a, c bottom row), an observation consistent with the capacity of active 
caspase-3-negative neurons expressing t1EK2-p53DN to occasionally enter M-phase (Fig. 10d, e). 
Therefore, although most neurons could not undergo G2/M transition, some neurons did enter M-
phase upon t1EK2 expression and p53 inhibition.  
 
Figure 13. Neuronal cell cycle progression is arrested in late G2. a Percentage of LacZ-p53DN 
(Control) or t1EK2-p53DN-expressing neurons with pH3 foci (Late G2) (Control: n=150; t1EK2-
p53DN: n=150) or pan-nuclear staining (M-phase) (Control: n=150; t1EK2-p53DN: n=150) at 1.5 dpt. 
Anaphase onset was blocked with MG132. Three independent experiments were carried out. As 
control neurons were never positive for pH3, statistical analysis was performed by comparing pH3-
positive t1EK2 neurons with zero (***p<0.001, *p<0.05; one-tailed t-test). b, c Fluorescence 
microscope images of pH3-negative control neurons (b) and pH3 positive t1EK2-p53DN expressing 
neurons (c). pH3 foci indicate late G2 (c, top row) and pan-nuclear pH3 staining M-phase (c, bottom 
row). See “Protocol to assess late G2 and M-phase” in page 35 for information on compound 
concentrations and timings. White arrows identify RFP positive neurons. Yellow arrows identify 
MAP2-negative glial cells. Graphs represent mean ± s.e.m. Scale bars: 25 µm.  
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4.7. t1EK2 induces DNA damage 
The G2/S-M checkpoints are activated by RS and prevent G2/M transition [52]. Deregulated Cyclin 
E can induce RS with both pan-nuclear and foci γ-H2AX staining patterns [136–138,191,195]. γ-
H2AX immunostaining is widely used to assess DNA damage and, in particular, DNA DSB are thought 
to be reflected by γ-H2AX foci  [179]. However, pan-nuclear γ-H2AX staining has also been argued 
to portray RS even in the absence of DNA DSB [204–206]. Thus, we assessed whether RS was 
present in t1EK2-p53DN expressing neurons by γ-H2AX. Staining with γ-H2AX at 1.5 dpt revealed a 
bimodal distribution between cells with 5 or fewer foci and more than 5 foci (Fig. 14a). The majority 
of t1EK2-expressing neurons presented more than 10 γ-H2AX foci or pan-nuclear γ-H2AX staining 
whilst control neurons largely presented between 1 and 5 γ-H2AX foci. The ubiquitous presence of 
γ-H2AX foci in control neurons was not unexpected, as previous reports indicate that neurons “self-
inflict” DNA DSB as part the physiological regulation of early response genes [207]. 
The same group of neurons was analyzed to determine whether t1EK2-p53DN treatment resulted 
in a significantly higher proportion of neurons with more than 5 γ-H2AX foci. Neurons presenting 
more than 5 γ-H2AX foci was significantly higher in the t1EK2-p53DN-expressing group (78 %) than 
in the p53DN-expressing controls (24 %) (p<0.001, Fisher’s exact test) (Fig. 14b). Neurons with γ-
H2AX staining generally displayed interphase nuclei (Fig. 14d, e left neuron). However, neurons 
presenting reduced γ-H2AX foci formation could be occasionally found with prophasic-like mitotic 
chromatin condensation (Fig. 14e right neuron). Hence, although they are not direct proof, these 
results are consistent with RS inducing an S-M checkpoint-dependent block of M-phase entry. 
Noteworthy, RAD51 immunostaining was also performed to assess DNA damage (Fig. 14f). RAD51 
is used as a marker of homologous recombination, an error-free form of DNA DSB repair that uses 
replicated sister chromatid strand to template (strand invasion) the repair of the damaged strand 
[208]. Consequently, it requires DNA replication and is therefore simultaneously evidence of cell 
cycle re-entry.  
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Figure 14. t1EK2 induces DNA damage. a Cumulative frequency of LacZ-p53DN control neurons 
(n=150) or t1EK2/p53DN (n=150) neurons at 1.5 dpt negative for γ-H2AX foci, with 1-5, 6-10 or more 
than 10 γ-H2AX foci or pan-nuclear γ-H2AX staining. The distribution of frequencies is bimodal, 
being grouped in either less or more than 5 γ-H2AX. b Subsequent analysis of percentage of control 
LacZ-p53DN or t1EK2-p53DN-expressing neurons with more than 5 γ-H2AX foci (Control: n=150; 
t1EK2/p53DN: n=150) at 1.5 dpt. Three independent experiments were carried out (***p<0.001; 
Fisher’s exact test). c, d Fluorescence microscope images of control neurons (c) with negative or 
pan-nuclear γ-H2AX staining and t1EK2-p53DN neurons (d) with more than γ-H2AX 10 foci (d top 
row) or pan-nuclear staining (d bottom row). e Confocal image of pan-nuclear γ-H2AX staining of 
an interphase nucleus (left neuron) and γ-H2AX foci of a prophase-like nucleus (right neuron). As it 
may not activate S-M checkpoint signaling, reduced DNA damage (right neuron with γ-H2AX foci) 
may be permissive of spontaneous G2/M transition. f Fluorescence microscope images of t1EK2-
p53DN neuron positive for RAD51, reflecting cell cycle-specific homologous recombination of 
double-stranded DNA damage. See “Protocol to assess late G2 and M-phase” in page 35 for 
information on compound concentrations and timings. Arrows identify RFP positive neurons. Scale 
bars: 25 µm.  
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4.8. Inhibition of Wee1 kinase enables M-phase entry 
Compounds that abrogate the ATM/Chk2-dependent G2 checkpoint and ATR/Chk1/Wee1-
dependent S-M checkpoint signaling are used to specifically induce the selective killing of p53-
deficient cancerous cells [52,206,209,210]. This is because p53-deficient cells heavily rely on G2 
arrest to amend DNA replication errors prior to M-phase entry, and therefore avoid mitotic 
catastrophe. Along these lines, ATR loss of function is particularly lethal to p53-deficient cells with 
Cyclin E-induced RS [195]. The G2/M transition is routinely enforced using caffeine to inhibit 
ATM/ATR [211] or okadaic acid to inhibit PP2A and PP1 [212], and likely other phosphatases. In 
addition, given the therapeutic potential in cancer treatment, selective inhibitors for ATM, ATR, 
Chk1, Chk2, and Wee1 are also readily available [52,206,209,210]. Inhibitors for ATM/ATR 
(caffeine), ATM (CP-466722) and ATR (VE-821) in combination or for Wee1 (MK1775) alone were 
tested in t1EK2-p53DN expressing neurons in preliminary studies (data not shown). All of the 
aforementioned treatments enabled G2/M transition. Nevertheless, quantification studies of G2/M 
transition were performed with the Wee1 kinase inhibitor MK-1775 [173] (Fig. 15).   
 
 
Figure 15. Protocol to assess G2/M phase transition after Wee1 inhibition. Oncogenes induce G1/S 
transition (1) and RS that can lead to p53-dependent apoptosis [3]. In turn, the loss of function of 
p53 affords viability and cell cycle progression (2). However, p53 dysfunction impairs the ATM-
dependent checkpoint program [52]. Thus, p53-deficient cells rely heavily on ATR-dependent G2 
arrest to amend DNA damage prior to M-phase entry (3). Downstream of ATR, G2 arrest relies on 
Wee1 kinase. Wee1 inhibition with MK1775 can abrogate the G2/S-M checkpoints and afford M-
phase entry (4) [173]. Anaphase onset was blocked with the proteasome inhibitor MG132 [171] to 
prevent the loss of pH3 signal in neurons that had entered M-phase during the duration of the 
experiment (5) [172].   
 
Control MAP2-positive neurons were not found in late G2 or M-phase (n=150) (Fig. 16a). In contrast, 
Wee1 inhibition with MK1775 resulted in an increase of t1EK2-p53DN-expressing neurons in M-
phase (31.3 %) (t149=8.246, p<0.001) (Fig. 16a, c, d). Alternatively, 37.3 % (t149=9.422, p<0.001) of 
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t1EK2/p53DN-expressing neurons were still found in late G2 as reflected by pH3 foci (Fig. 16a, b). 
The total percentage of neurons in late G2 and M-phase after Wee1 inhibition (68.6 %) was 
consistent with the percent of BrdU positive neurons at 2 (61.2 %) or 3 dpt (61.8 %) (Fig. 11a).  
 
 
Figure 16. Inhibition of Wee1 
kinase enables M-phase 
entry: pH3 
immunocytochemistry. a 
Percentage of LacZ-p53DN 
(Control) or t1EK2-p53DN 
expressing neurons (Control: 
n=150; t1EK2-p53DN: n=150) 
at 1.5 dpt in late G2 or in M-
phase after G2 checkpoint 
abrogation with MK1775. 
Anaphase onset was blocked 
with MG132. Three 
independent experiments 
were carried out. As control 
neurons were never positive 
for pH3, statistical analysis 
was performed by comparing 
pH3-positive t1EK2-p53DN 
neurons with zero 
(***p<0.001; one-tailed t-
test). b-d Confocal images 
and 3D reconstructions of a 
pH3 foci-positive neuron 
consistent with late G2 (b) 
and neurons with pan-
nuclear pH3 staining 
consistent with 
prometaphase/metaphase 
(c, d). See “Protocol to assess 
G2/M phase transition after 
Wee1 inhibition” in page 35 
for information on compound 
concentrations and timings. 
Arrows identify RFP positive 
neurons. Graphs represent 
mean ± s.e.m. Scale bars: 25 
µm. 
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Neuronal M-phase was further confirmed by anillin immunolabelling. Anillin shuttles from the 
nucleus to the cell cortex during NEB during the prophase to prometaphase transition [213]. In 
neurons with nuclei showing prometaphase/metaphase nuclear morphology, anillin 
immunostaining was released from the cell nucleus as expected (Fig. 17a). We also performed α-
tubulin immunostaining of the mitotic spindle of neurons in M-phase. Although α-tubulin staining 
resulted in extensive background signal due to its presence in the cytoskeleton, putative mitotic 
spindles with intense α-tubulin labeling could be identified in neurons with chromatin 
condensation, consistent with prometaphase/metaphase (Fig. 17b, c).  
 
Figure 17. Inhibition of Wee1 
kinase enables M-phase entry: 
Anillin and γ-tubulin 
immunocytochemistry. a 
Confocal images of a t1EK2-
p53DN-expressing neuron with 
anillin immunostaining. Anillin is 
no longer confined to the nucleus, 
indicating NEB. b, c Confocal 
images of t1EK2-p53DN-
expressing neurons with α-tubulin 
immunostaining of putative 
mitotic spindles. Bottom panels: 
projection of slices 1 to 23 (b) and 
1 to 16 (c) out of 50 to eliminate 
background of cytoskeletal α-
tubulin staining. See “Protocol to 
assess G2/M phase transition 
after Wee1 inhibition” in page 35 
for information on compound 
concentrations and timings. 
Arrows identify RFP positive 
neurons. Graphs represent mean 
± s.e.m. Scale bars: 25 µm (a-c), 10 
µm (b, c bottom panels). 
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Finally, we performed time-lapse experiments in t1EK2-p53DN expressing neurons to follow live 
cell cycle progression into M-phase. To study chromatin dynamics, we expressed H2B-GFP and RFP 
to study overall morphology [167]. Time-lapse experiments confirmed neurons co-expressing 
t1EK2-p53DN reached M-phase (Fig. 18a, b, c left neuron) or remained with interphase morphology 
(Fig. 18d). M-phase entry usually involved a loss of RFP signal from dendrites (Fig. 18a, b). These 
changes are consistent with the altered morphology seen in neurons in between prometaphase 
and metaphase from previous immunocytochemistry experiments (Fig. 13c bottom row; Fig. 16c, 
d), which was not evident in neurons in late G2 (Fig. 13c top row; Fig. 16b). This may reflect an 
attempt at mitotic cell rounding and or effects associated with the loss of nuclear-cytoplasmic 
compartmentalization during NEB.   
 
Figure 18. Inhibition of 
Wee1 kinase enables 
M-phase entry: Time-
lapse. a-d Time-lapse 
video frames of t1EK2-
p53DN expressing 
neurons after inducing 
G2/M transition. 
Dendrites appear to 
undergo dendritic 
retraction or thinning 
concomitantly to mitotic 
chromatin condensation 
(a, b, c left neuron). 
Morphological 
alterations are not 
apparent in cells that 
remain with interphase 
nuclear morphology (c 
right neuron, d). See 
“Protocol to assess 
G2/M phase transition 
after Wee1 inhibition” in 
page 35 for information 
on compound 
concentrations and 
timings. H2B: Histone 
H2B tagged with EGFP. 
Scale bars: 25 µm. 
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4.9. Neurons can undergo cytokinesis 
Time-lapse experiments showed neurons were not found to undergo anaphase/cytokinesis after 
abrogation of G2/S-M checkpoint signaling with the Wee1 kinase inhibitor MK1775 (n=300). 
Anaphase and cytokinesis in M-phase can be precluded as a result of RS in S-phase [67]. RS can 
result in aberrant DNA structures (e.g. partially replicated or re-replicated DNA resulting in fused 
sister chromatids) that, if carried into M-phase, can become physical barriers that irreversibly 
prevent anaphase/cytokinesis [67]. Physical barriers to anaphase and cytokinesis often come in the 
form of chromosome bridges (also known as anaphase bridges), wherein stretches of DNA are 
attached to oppositely receding sister chromatids (although they can also result from merotelic 
attachments) [45,67]. If unresolved, these bridges inevitably traverse the plane of division during 
cytokinesis, preventing abscission and often leading to multinucleation and or micronucleation  
[67]. Cyclin E deregulation is known to result in RS [136–140,191–195], and RS was congruent with 
G2 arrest (Fig. 13a), the presence of γ-H2AX (Fig. 14b), and Wee1-dependent regulation of G2/M 
transition (Fig. 16a) in t1EK2-p53DN expressing neurons. Cyclin E LMW isoforms are associated to 
the formation of chromosome bridges and multinucleation [142,143]. Active caspase-3-negative 
t1EK2-p53DN expressing neurons did present chromosome bridges (Fig. 10d top row) and 
multinucleation (Fig. 7d bottom row). RS can result in chromatin bridges that physically and 
irreversible block cytokinesis in neurons, which contrasts with the reversible block exerted by cell 
cycle checkpoints in S, G2 and M-phase [3,48,49,52,206,209,210].  
Strategies to reduce RS were devised to enable the study of anaphase/cytokinesis in neurons. 
Excess origin firing associated with deregulated Cyclin E [137,138,140] was considered as a potential 
source of RS in neurons. It was hypothesized that excess origin firing may result in increased dsSCI. 
The appearance of dsSCI results from fork convergence during normal DNA replication [214]. As 
replication forks approximate each other, torsional stress increases ahead of the forks and makes 
the DNA strands inaccessible, therein blocking DNA replication. To relieve torsional stress and make 
the region accessible for DNA replication, fork rotation is thought to unwind the strands ahead of 
the replication forks. However, this translates into the winding of the 4 strands of DNA behind the 
replication forks, which results in dsSCI in the form of DNA precatenanes. The resolution of these 
forms of dsSCI is mainly dependent on TOP2α [214]. As noted, TOP2α decatenase activity of dsSCI 
is required to prevent decatenation checkpoint-dependent arrest in G2 [54]. In addition, within M-
phase, insufficient TOP2α-dependent decatenation of dsSCI can also result in the delay of anaphase 
[215–218]. Instead of insufficient decatenation of dsSCI between chromosome arms as in the G2 
decatenation checkpoint, anaphase delay is activated by unresolved centromeric dsSCI [217,218]. 
In addition, TOP2α dysfunction results in the accumulation of UFB [218–222]. In contrast with bulk 
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chromosome bridges, UFB are a type of bridges that cannot be stained commonly used DNA dyes.  
Gathering the above, it was hypothesized that t1EK2 induced excess origin firing, leading to the 
accumulation of dsSCI, which could result in anaphase delays and the formation of chromosome 
bridges and UFB. Hence, t1EK2-p53DN was co-expressed with TOP2α [168] with the objective of 
aiding in the resolution of dsSCI. In addition, caffeine was used to abrogate G2/S-M checkpoints 
because it inhibits both ATM and ATR upstream of Wee1, therein also resulting in the inhibition of 
Myt1 and disinhibition of Cdc25 phosphatases [52,206,209–211]. Henceforth, anaphase and 
cytokinesis was studied in neurons co-expressing t1EK2-p53DN-TOP2α after the abrogation of G2 
and S-M checkpoint signaling with caffeine (Fig. 19).   
     
Figure 19. Protocol to assess cytokinesis. Oncogenes induce G1/S transition (1) and RS that can 
lead to p53-dependent apoptosis [3]. In turn, the loss of function of p53 affords viability and cell 
cycle progression (2). However, p53-deficient cells rely heavily on ATR-dependent G2 arrest to 
amend DNA damage prior to M-phase entry (3) [52]. As Wee1 inhibition with MK1775 (4) [173], 
ATM/ATR inhibition with caffeine can abrogate G2 arrest and afford M-phase entry (5) [211]. Once 
in M-phase, unresolved dsSCI can result in anaphase delays (6)  [215–218]. Decatenation of dsSCI is 
mainly TOP2α dependent (7) [214]. Hence TOP2α was co-expressed with t1EK2-p53DN to facilitate 
the resolution of dsSCI, which was hypothesized to aid in anaphase/cytokinesis onset. 
 
We performed time-lapse experiments in t1EK2-p53DN-TOP2α expressing neurons. Chromatin 
dynamics were followed by H2B-GFP and overall morphology was assessed by RFP. As a cautionary 
note, the photon flux generated to extract a signal from the fluorophores during time-lapse 
experiments damages cells (photo-toxicity). Photo-toxicity is reported to reverse cells in prophase 
to G2 [223], which is reminiscent of the antephase checkpoint [53]. Thus, to reduce the deleterious 
effects of fluorescent imaging, only a selection of RFP positive neurons was made for each study 
(see Materials and Methods for additional details). In consequence, the sample size to detect an 
event that already has a low probability of occurrence was greatly reduced.  
As described in the introduction, anaphase and cytokinesis onset signaling is overlapping. Hence, 
the visualization of anaphase without obvious cleavage furrow ingression does not necessarily 
imply that the cytokinesis machinery has not been engaged. The onset of anaphase, as indicated by 
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receding chromatin, and cytokinesis, as indicated by cleavage furrow ingression, was therefore not 
quantified as separate events. Namely anaphase and cytokinesis were accounted for together. 
Anaphase/cytokinesis could be detected in 12.9 % (n=93) of t1EK2-p53DN-TOP2α expressing 
neurons, with most undergoing anaphase/cytokinesis failure (n=8) (Fig. 20a-d). As expected, 
cytokinesis failure after karyokinesis onset resulted in neurons presenting multiple nuclei and or 
micronuclei (Fig. 20a-d). Cleavage furrow ingression was not visible in most cases (Fig. 20a-c), 
although it could be occasionally detected (Fig. 20d). Dendritic thinning/retraction was detected in 
M-phase (Fig. 20d). Surprisingly neurons appeared to be able to recover the dendrites, as indicated 
by RFP, upon what appeared to be cell cycle exit, as indicated by H2B-GFP (Fig. 20d). Loss of RFP 
signal in neurons during M-phase (Fig. 20d) was unlike evident dendritic deterioration during cell 
death in interphase (Fig. 20e). Finally, loss of RFP signal from dendrites did not take place in neurons 
that remained with interphase nuclear morphology (Fig. 20f).  
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Figure 20. Neurons can undergo cytokinesis: Anaphase/cytokinesis failure time-lapse. a-c Time-
lapse video frames of putative neurons undergoing multinucleation captured from 
metaphase/anaphase (a), anaphase (b, top neuron) and interphase (c) or already presenting 
multinucleation (b, bottom neuron). Putative neurons could present binucleation with visible 
chromatin stretches linking nuclei (b, top neuron) or higher multinucleation (a). The white asterisk 
marks the time frame at which anaphase is first detected. White arrow point to nuclei remaining 
after M-phase. d Putative neuron undergoing cytokinesis failure. Cleavage furrow ingression 
(white arrowhead) appears to position the plane of division between a small aggrupation of 
chromatin (yellow arrow) and a larger one (white arrow). RFP signal from the dendrites is lost 
from the dendritic shaft concomitant to M-phase and recovered after putative M-phase exit 
(yellow pound mark). In contrast, some distal processes increase the RFP signal during M-phase 
and revert to apparent normality after putative M-phase completion (white pound mark). At least 
in this case, it seems like a redistribution of RFP signal rather than dendritic retraction is taking 
place. Other processes lost in M-phase do not appear to be recovered. e Time-lapse video frames 
of putative neuron undergoing cell death in interphase. f Time-lapse video frames of putative 
neuron remaining with nuclear morphology consistent with interphase. See “Protocol for G2 
synchronization and release” (d) and “Protocol for prometaphase synchronization and release” 
(a-c, e, f) in page 35 for information on compound concentrations and timings. H2B: Histone H2B 
tagged with EGFP. Scale bars: 25 µm. 
 
Some neurons appeared to be able to complete cell division (n=4) (Fig. 21a-g). After what 
appeared to be complete abscission, both daughter cells could apparently die (Fig. 21a) or 
only one could apparently remain viable (Fig. 21d, e). Alternatively, both daughter neurons 
could remain apparently viable (Fig. 21b, c, f, g). Aneuploidy is evident in all of the surviving 
neurons (Fig. 21b-g). At least 12 nuclei/micronuclei can be counted in one neuron (Fig. 21g 
left neuron) whilst dramatic genomic loss is evident in another (Fig. 21c left neuron). 
Aneuploidy can explain the heterogeneous viability (Fig. 21d, e) and differences in MAP2 
staining (Fig. 21g) of daughter neurons. Of note, electron microscope imaging is arguably 
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required to attest to full abscission in some cases (Fig. 21b, c). Nevertheless, in as much as 
one daughter neuron has been shown to survive and the other die (Fig. 21d, e), it is 
undeniable that neurons can complete abscission. If abscission was not complete, both 
neurons would have died.  
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Figure 21. Neurons can undergo cytokinesis: Anaphase/cytokinesis time-lapse. a-g Time-lapse 
video frames and confocal images of cytokinesis. a Putative neuron apparently dying during 
cytokinesis. What appears to be the axon is lost during cell death (white arrowheads). b Neuron 
undergoing cytokinesis. The white asterisk marks the time of cleavage furrow ingression. Yellow 
and white arrows mark the soma separated by the plane of division. Yellow indicates the portion of 
the soma that contains chromatin that is only visible in c. c Confocal images of b. One portion of 
the soma contains three small nuclei (yellow arrow) that are separated from the rest of the 
chromatin (white arrow). d Neuron undergoing protracted cytokinesis, with one of the daughter 
neurons remaining viable (white arrow) and the other undergoing cell death (yellow arrow). The 
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white asterisk marks the time of anaphase onset.  Initial cleavage furrow ingression appears to take 
place at two sites white arrowheads). e Confocal images of d. f Neuron undergoing swift cytokinesis, 
with both daughter neurons appearing viable. The white asterisk marks the time of cytokinesis. g 
Confocal microscope images of f. One of the daughter neurons is multinucleated (yellow arrow), 
whilst the other has a faint MAP2 signal (white arrow). See “Protocol for G2 synchronization and 
release” (f, g) and “Protocol for prometaphase synchronization and release” (a-e) in page 35 for 
information on compound concentrations and timings. H2B: Histone H2B tagged with EGFP. Scale 
bars: 25 µm. 
 
The assembly of the cytokinesis machinery was further assessed by anillin immunocytochemistry. 
Anillin localizes to the cleavage furrow at cytokinesis onset and thereafter remains in the 
intercellular bridge [213]. As seen in time-lapse experiments, the onset of cytokinesis from the time 
of G2/S-M checkpoint abrogation could be many hours apart and its duration could last from 
minutes to several hours. Neurons did not undergo cytokinesis in synchrony. Hence, capturing 
neuronal cytokinesis in the moment of fixation for anillin immunocytochemistry was highly unlikely. 
Anaphase/cytokinesis onset was experimentally induced to synchronize neurons for 
immunocytochemistry experiments. This was achieved by abrogating the SAC, which arrests cells 
at metaphase [40], with the Mps1 kinase inhibitor AZ3146 [58] (Fig. 22). SAC abrogation inherently 
entails that anaphase/cytokinesis onset will be premature, and thus undermines the successful 
completion of cell division. This strategy was not designed to improve the chances of cytokinesis 
completion, but to improve the chances of observing ongoing cytokinesis. Of note, cell division 
cannot be faithfully identified once it has been completed, as the only “after the fact” indicator is 
the proximity between RFP positive cells. The latter cannot guaranty cells have in fact divided, 
despite they do suggest the possibility.  
Anillin immunostaining confirmed the prophase/prometaphase transition (Fig. 23a), the assembly 
of the cytokinesis machinery (Fig. 23b, c, f, g) and indicated the presence of putative daughter 
neurons (Fig. 23d, e). As expected, anillin stained the final stages of cleavage furrow ingression or 
midbody (Fig. 23b, c). DAPI-positive chromosome bridges were traversing the plane of cleavage 
furrow in most cases (Fig. 23b, g). Although there were some exceptions (Fig. 23c), UFB bridges 
could not be ruled out. Of note, it stands to reason that ongoing cytokinesis involving bulk 
chromosome bridges are the easiest to detect because they delay abscission for hours (Fig. 21a, d). 
Neurons in close proximity that appeared to have completed abscission were also detected (Fig. 
23d, e).  
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Figure 22. Protocol to assess cytokinesis after Mps1 inhibition. Oncogenes induce G1/S transition 
(1) and RS that can lead to p53-dependent apoptosis [3]. In turn, the loss of function of p53 affords 
viability and cell cycle progression (2). However, p53-deficient cells rely heavily on ATR-dependent 
G2 arrest to amend DNA damage prior to M-phase entry (3) [52]. As Wee1 inhibition with MK1775 
(4) [173], ATM/ATR inhibition with caffeine can abrogate G2 arrest and afford M-phase entry (5) 
[211]. Once in M-phase, anaphase onset is restricted by the SAC [40] (6). The SAC responds to 
improper attachments between kinetochores and k-fibers. This SAC response requires Mps1-
dependent targeting of Mad2 to the kinetochores, which in turn sequesters Cdc20 away from APC/C 
[40,56–61]. The sequestration of Cdc20 prevents APC/CCdc20 mediated destruction of Cyclin B1 and 
securin, which are required for anaphase onset. The SAC can be abrogated by inhibition of Mps1 
with AZ3146 (7) [58], therein inducing anaphase/cytokinesis. The presence of dsSCI also results in 
a Mad2-dependent anaphase delay but does not require kinetochore targeting of Mad2 [215,216] 
nor Mps1 activity [56]. TOP2α was co-expressed with t1EK2-p53DN to facilitate the resolution of 
dsSCI (8) and, presumably, prevent non-kinetochore targeted Mad2-dependent SAC. As a 
cautionary note, AZ3146 was used to induce anaphase in neurons synchronously by SAC abrogation, 
which “by definition” will result in premature anaphase. AZ3146 treatment can also interfere with 
Mps1-dependent chromosome alignment during prometaphase to metaphase [58]. Moreover, 
premature SAC abrogation and ensuing Cyclin B1 degradation can induce mitotic slippage [171]. 
Thus, Mps1-inhibition prior to metaphase will likely result in chromosome misalignment or mitotic 
slippage (A) whilst SAC abrogation will inherently result in premature anaphase/cytokinesis (B), 
which will itself reduce the chances of cytokinesis completion.  
 
Cytokinesis was atypical. At initial stages of cytokinesis, the positioning of the cleavage furrow was 
asymmetric, and so was further furrow ingression (Fig. 23f, g). Instead of forming a ring around the 
entire soma in coordination with anaphase, anillin was detected on one side of the neuronal soma 
and often ahead of anaphase (Fig. 23f). Furrow ingression seemed to proceed asymmetrically in a 
“zipper-like” fashion (Fig. 23g). This asymmetric cleavage furrow ingression is reminiscent of NE 
cells. As indicated by anillin, cleavage furrow ingression has been described to begin in the basal 
process, away from the soma, and proceed asymmetrically towards and through the soma in the 
apical direction in mouse and zebrafish NE cells [224]. In the case of the neurons described here, 
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anillin staining was first detected on one side of the soma rather than in any process, but it did 
appear ahead of anaphase (Fig. 23f) and its progression was asymmetric (Fig. 23g). Whether this 
bears relation to an inherited form of NE cytokinesis or it is simply an artifact inherent to the 
protocol (e.g. forced anaphase) and or cell-culture system (e.g. growth in 2 dimensions rather than 
3) remains to be determined.  
Immunostaining for pH3 was also performed. The loss of pH3 staining begins at anaphase and is 
completed at telophase [172]. Pan-nuclear pH3 positive neurons mostly presented chromatin 
condensation morphology consistent with prophase or prometaphase (data not shown). As a result, 
SAC abrogation to elicit anaphase onset was instead likely resulting in mitotic slippage (see Fig. 22 
for explanation).  Notwithstanding, neurons with chromosome bridges were found (Fig. 23h). 
Nucleus presented mixed pH3 staining. Chromatin forming the chromosome bridge and in close 
proximity to the intercellular bridge was pH3 positive whilst pH3 negative chromatin was distal to 
the bridge and apparently undergoing decondensation. The latter is consistent with the loss of pH3 
during telophase and the former with an active abscission checkpoint. Histone H3 is phosphorylated 
at Ser10 (pH3) by Aurora A/B kinases [225], and Aurora B is necessary to prevent the recession of 
the cleavage furrow when the abscission checkpoint is active [45]. This provides time to resolve the 
chromosome bridge and facilitates abscission, as cleavage furrow regression in response to the 
bridge would otherwise result in tetraploidization. The presence of a functional abscission 
checkpoint in neurons could explain pH3 positive bridges and why cytokinesis duration can be 
protracted but nevertheless executed. Neurons may be actively resolving the chromatin bridges in 
an effort to undergo cell division. Future studies will have to address this possibility.  
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Figure 23. Neurons can undergo cytokinesis: Immunocytochemistry. a-g Confocal images of anillin 
immunolabelling. Anillin is released from the nucleus after NEB during prometaphase (a) and stains 
the cleavage furrow/midbody during neuronal cytokinesis (b, c, f, g). Anillin is recycled from the 
midbody in putative daughter neurons after completing abscission (d, e). Cleavage furrow 
ingression onset appeared to be asymmetrical (f). Chromatin was generally in the plane of division 
forming chromatin bridges (b, g) but were occasionally not apparent (c). h Confocal images of a pH3 
positive neuron undergoing cytokinesis. White arrows identify prometaphase-like nucleus (a), the 
plane of furrow ingression (b, c, f, g), separating daughter neurons (h) and putative daughter 
neurons (d, e). See “Protocol for anaphase synchronization” in page 35 for information on 
compound concentrations and timings. Blue, red and green arrows represent 3D orientation (a-e, 
h). Scale bars: 25 µm.  
 
4.10. AIS is lost in M-phase and recovered after cell cycle exit without cytokinesis 
Neurons displayed morphological changes upon entry into M-phase. These morphological 
alterations could reflect that neurons actively adapt their biology to enable the cell cycle, which 
may be necessary. Neurons have highly specialized functions that, without additional regulatory 
mechanisms, may not be compatible with a standard cell cycle. Hence, even if S, G2, and M-phase 
in neurons are normal, it is likely that their differentiated status requires additional adaptations for 
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the cell cycle to be a viable program. To garner insights into the nature of neuronal adaptations, we 
assessed changes in the AIS along the cell cycle. The AIS sustains neuronal polarity and integrates 
synaptic input to generate action potentials [226,227]. Further, the AIS integrity is required to 
maintain neuronal viability [227,228]. Hence, alterations in AIS integrity can potentially reflect an 
adaptation of neuronal excitability to the cell cycle whilst doubling as an indicator of cell viability. 
AnkG is the main protein in the AIS [226]. Thus, we analyzed AnkG immunostaining across different 
phases within the cell cycle and after cell cycle exit.  
There were several important caveats that prevented the study of AIS after cytokinesis completion. 
Cytokinesis was a rare event even when aberrant and physiological-like cytokinesis was inexistent. 
Hence, it was not easily amenable to study. The patent aneuploidy resulting from aberrant 
cytokinesis had unpredictable effects in the genome of daughter neurons. For example, one of the 
daughter neurons could die and the other survive (Fig. 21e) or one could retain strong MAP2 
staining whilst the other did not (Fig. 21g). Insofar it is not possible to discriminate between the 
effects of an altered gene dosage on viability from that of cytokinesis itself, any interpretation of 
the results would be biased. Instead, cell cycle exit was studied in multinucleated neurons, which 
albeit also aneuploid at least are far more likely to conserve the original genome. Critically, neurons 
are reported to re-enter the cell cycle and remain viable without undergoing cell division in AD [93] 
and multinucleated neurons have been reported in AD patients [229], yet there are no models of 
re-entry and exit that can afford insights into how these neurons survive. AIS was assessed in 
control LacZ-p53DN-TOP2α-expressing neurons and t1EK2-p53DN-TOP2α-expressing neurons in 
interphase, prophase, in between prometaphase and telophase and after multinucleation. 
Prometaphase, metaphase, anaphase, and telophase could not be reliably distinguished from each 
other based on chromatin morphology alone but they could be distinguished from prophase. 
Hence, the AIS in M-phase was studied accordingly. AIS was assessed in all groups after the G2/S-
M checkpoint and SAC abrogation. Interphase and M-phase neurons were fixed 3 hours after G2/S-
M checkpoint abrogation, one group of multinucleated neurons 6 hours after and another 9 hours 
after. This allowed determining whether there was a progressive recovery of the AIS after cell cycle 
exit. Finally, the control group was also fixed for immunocytochemistry 9 hours after G2/S-M 
checkpoint abrogation. 
AnkG signal changed throughout the cell cycle [Welch’s F test (5; 20,479) = 11.617, p<0.001] (Fig. 
24a, b). Games-Howell post-hoc multiple comparisons revealed AnkG signal of neurons in prophase 
was the same as for neurons in interphase (p=0.448) or controls (p=0.703). Neurons in between 
prometaphase and telophase did have a decrease in AnkG when compared to interphase (p=0.003), 
prophase (p=0.023) or control (p=0.009) neurons. The signal was still reduced 6 hours after G2/S-
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M checkpoint abrogation in multinucleated neurons when compared to interphase (p=0.033), 
prophase (p=0.033), or control neurons (p=0.041). In contrast, 9 hours after G2/S-M checkpoint 
abrogation multinucleated neurons had significantly increased their AnkG signal in comparison to 
neurons in between prometaphase and telophase (p=0.005). When these multinucleated neurons 
were compared to multinucleated neurons fixed 3 hours before, they presented a non-significant 
tendency in the increased their AnkG signal (p=0.065) and the signal was no longer statistically 
significantly different from control neurons (p=0.957) and neurons in interphase (p=0.999) or 
prophase (p=0.349). Hence, AnkG was lost in M-phase and progressively recovered after premature 
cell cycle exit.  
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Figure 24. AIS is lost in M-phase and recovered after cell cycle exit without cytokinesis. a AnkG 
signal per µm in t1EK2-p53DN-TOP2α-expressing neurons in different stages of the cell cycle (green) 
and in control neurons expressing LacZ-p53DN-TOP2α (blue) at the indicated time points after 
suppressing the G2 checkpoint with MK1775. AnkG is normalized to neighboring RFP-
negative/MAP2-positive neurons. All groups were treated with AZ3146 to abrogate the SAC 2.5 h 
after MK1775 treatment. A single experiment was carried out (**p<0.01, *p<0.05; Welch’s F test 
and two-sided Games-Howell post-hoc tests; Interphase: n=9, Prophase: n=7, Prometaphase to 
telophase: n=9, Multinucleation 6 h: n=8, Multinucleation 9 h: n=10, Control: n=10). b Confocal 
images of AnkG-immunolabelled neurons in interphase, prophase, and prometaphase to telophase, 
multinucleated neurons 6 and 9 h post transfection, and control neurons. High magnification of AIS 
(boxes) is shown for each case. Arrowheads identify RFP positive neurons and arrows their 
respective AIS when present. Graphs represent mean ± s.e.m. Scale bar: 25 µm. 
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5. Discussion 
The results show that t1EK2 and EK2 induce cell cycle re-entry in neurons. t1EK2 triggers p53-
dependent apoptotic cell cycle related cell death. Viability is rescued to control levels by the loss of 
function of the tumor suppressor p53. This is reminiscent of oncogenic deregulation in mitotic cells, 
in which loss of p53 function enables the escape of cell death and or senescence [3]. ATM/ATR 
checkpoint signaling lays upstream of p53 activation [48,49,52], which suggests that t1EK2 induces 
ATM/ATR-dependent checkpoint signaling and p53-dependent cell death in neurons. However, p53 
signaling results in cell death downstream of events that are independent of cell cycle checkpoint 
signaling [230]. Thus, further studies are necessary to unequivocally establish p53-dependent cell 
death signaling is downstream of the aforementioned checkpoints. Nevertheless, contrary to what 
has been suggested [94–96], the results show cell cycle re-entry related cell death is not an 
inescapable consequence of neuronal cell cycle re-entry.  
After rescue from cell death by p53DN, some neurons do spontaneously enter M-phase. Hence, as 
opposed to what was previously thought [93], M-phase entry is not prohibited in neurons. 
Nevertheless, the vast majority of neurons do not enter M-phase. The G2/S-M checkpoints gate M-
phase entry and can be activated by RS [52]. Deregulated Cyclin E can induce γ-H2AX staining 
indicative of RS [136–138,191,195] and neurons expressing t1EK2-p53DN present heightened γ-
H2AX staining (Fig. 14a). This is congruent with the possibility that t1EK2-induces RS in neurons, 
which in turn elicits the activation of the G2/S-M checkpoints and results in the blockade of G2/M 
transition. However, two limitations to these studies should be mentioned. First, γ-H2AX foci 
increase as part of normal DNA replication during S-phase [179]. Adequate assessment of γ-H2AX 
immunostaining for RS detection requires a control group undergoing S-phase without RS to 
establish a baseline. As there are no known ways to induce a physiological RS-free S-phase, this is 
impossible to do in neurons. Also, control neurons occasionally presented pan-nuclear γ-H2AX (Fig. 
14c). RS could not account for this pattern of staining because control neurons did not re-enter the 
cell cycle (Fig. 7a; Fig. 8a; Fig. 11a; Fig. 13a). Apoptotic cell death can also result in γ-H2AX 
immunostaining [179], but apoptosis was virtually inexistent in control cells expressing p53DN at 
1.5 dpt (Fig. 10a). Finally, pan-nuclear γ-H2AX staining has also been described in cells driven to 
senesce from G1 [231]. Senescence can be induced in quiescent cells [5] and a cell cycle unrelated 
senescence-like phenotype has already been described in neurons [71–77]. Multiple stressors can 
induce senescence including DNA damage and oxidative stress and senescence can be p53-
independent [2]. Lipofection itself is stressful, especially to mature neuronal cultures. Thus, one 
possibility is that lipofection itself was triggering senescence, but this possibility was not further 
studied.  
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Neurons readily enter M-phase after the abrogation of G2/S-M checkpoint signaling by inhibiting 
Wee1 with MK1775 but also by inhibiting ATM/ATR with caffeine. This evidences that the block on 
M-phase entry is an active response, not the consequence of a dysfunctional cell cycle machinery. 
In contrast with M-phase entry, neurons were not readily found attempting anaphase and 
cytokinesis. This is to be expected, as Cyclin E deregulation results in RS [136–138,191,195] and RS 
can result in physical structures that irreversibly preclude the completion of cell division [67]. Co-
expression of TOP2α appears to improve the chances of cell division. Even within the framework of 
a deregulated cell cycle, neurons are evidenced to be able to undergo cytokinesis.  
Several cautionary notes have to be made regarding TOP2α. The use of the decatenase was based 
on the hypothesis that t1EK2 was resulting in RS by eliciting excess origin firing, increased fork 
convergence and consequently dsSCI. Cyclin E deregulation has been associated to excess origin 
firing [137,138,140], but whether this increases the number of dsSCI intertwines as a consequence 
of excess fork convergence and results in RS has not been addressed by research. Cyclin E has also 
been evidenced to prevent origin licensing in continuously cycling cells by impairing the loading of 
MCM2/4/7 [193] (but see [24,30,31,232]), which is at odds with excess origin firing also reported 
to result from Cyclin E deregulation [137,138,140]. To address a potential lack of dormant origins, 
in initial studies a seven phosphomimetic MCM2 mutant protein that self-loads to the chromatin 
[232] was co-expressed with t1EK2-p53DN. This did not appear to enable anaphase/cytokinesis in 
neurons (data not shown). However, it should be noted that MCM4/7 were more severely affected 
by Cyclin E overexpression than MCM2 in previous reports in mitotic cells [193], so the MCM2 
mutant was more than likely insufficient to guaranty sufficient dormant origins were available. 
Finally, the present work does not determine whether there is an increase or decrease of dormant 
origins, firing origins, dsSCI nor whether the co-expression of TOP2α aids in their decatenation to 
facilitate anaphase/cytokinesis. Notwithstanding, the objective of this work was not to identify new 
carcinogenic mechanisms, but to determine the extent to which neurons and mitotic cells share cell 
cycle regulation.  
Whether neurons are viable after cell division is not determined by the present work. Albeit 
undoubtedly alluring, any analysis of viability after neuronal cell division amidst clear aneuploidy 
and p53DN expression is severely biased and, ultimately, anecdotic. However, the analysis of the 
AIS in multinucleated neurons, which at least conserve the original genome, shows the neuronal 
cell cycle is a coordinated program. Neurons lose the AIS during M-phase and recover it after cell 
cycle exit without cell division. Further, RFP signal from dendrites also appears to be lost in M-phase 
and recovered after cell cycle exit. This is unexpected, as there is no reason to believe a coordinated 
cell cycle program is of any use to neurons. Still, if neurons are like mitotic cells, it is likely that their 
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cell cycle abides by general adaptations of differentiated functions as in other mitotic cells. For 
example, the loss/gain of the AIS and dendritic alterations may be a byproduct of mitotic cell 
rounding, not a neuron-specific adaptation of the axon to the cell cycle.  
Future work will have to endeavor into the many possibilities that have been opened. For now, the 
present results make it unquestionable that fully differentiated matured primary neurons and 
mitotic cells share the regulation and function of the cell cycle. This calls for a reconsideration of 
the postmitotic status of neurons as well as a new lecture on previous research of the neuronal cell 
cycle.  
5.1. A mitotic re-interpretation of postmitotic literature. 
The postmitotic status of neurons was originally believed to entail an irreversible withdrawal from 
the cell cycle. However, in humans, cell cycle markers have been reported in multiple neuron 
diseases [92,93] and aberrant neuronal cell cycle re-entry is associated with AD in particular 
[135,233–240]. Cell cycle related cell death in neurons has been linked to G0/G1/S signaling 
[90,94,97,98,101,102,104,108,109,114–128,132–134,233–235,241–258]. In neurons, the 
upregulation of Cyclin D1-Cdk4/6 [102,104,109,133,234,235,241,246–249] (but see [108]) and 
Cyclin E-Cdk2 [104,108,114,121,122,124,125,128] signaling has been associated with cell cycle 
related cell death. In particular, E2F1 is thought to have a major role in neuronal death 
[94,122,123,126,134,246,248,250–256], which has been associated to p53 signaling [242,257,258] 
but has also been shown to be mechanistically independent from p53 [126,242]. Finally, aberrant 
activation of Cyclin B1, Cdk1 and other regulators of G2/M transition, including Wee1, are 
associated with neuron diseases [105,106,112,234,237–240,259–261]. Given these reports, it has 
been suggested that the cell cycle machinery in neurons is redirected towards apoptotic signaling 
[94–96]. That is, unlike in mitotic cells, the cell cycle machinery of neurons is tasked with driving 
cell death.  
The above appears to presuppose that the cell cycle machinery of mitotic cells can only result in 
cell division. Far from it.  Cyclin D overexpression has been shown to elicit apoptosis in mitotic cells 
and in immature neurons alike [241]. It is well established that excess E2F1 activation during cell 
cycle re-entry in mitotic cells results in p53-dependent and independent cell death instead of cell 
division in mitotic cells [63]. Even after successful activation of DNA replication, DNA damage during 
S-phase can elicit cell death or senescence via E2F-independent signaling [3], which can result from 
overactivation of CycE-Cdk2 [137,138,197]. Beyond G1/S, prolonged activation of CycB1-Cdk1 also 
results in cell death of mitotic cells in M-phase [4,69]. Finally, neurons do not always die upon re-
entry either in vitro or in vivo [93,135,189,190,262]. Hence, the literature describing cell cycle 
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related cell death in neurons may be tapping on the same mechanisms that are already extensively 
characterized in mitotic cells. The results described herein clearly support that cell cycle pathology 
in neurons cannot be interpreted in isolation of standard mitotic biology.  
In mitotic cells, oncogenes that drive unscheduled cell cycle re-entry are considered the cause of 
pathology because they deregulate the cell cycle [67,263]. The cell cycle in itself is harmless for 
mitotic cells. In neurons, in contrast, any form of cell cycle activity is considered pathological. 
Consequently, drivers of the neuronal cell cycle program such as Aβ [125–130] are thought to result 
in cell cycle related cell death because any form of cell cycle activity is invariantly fatal to neurons. 
The present work offers an alternative interpretation. Results indicate that t1EK2 itself is likely the 
agent causing cell cycle deregulation in neurons, and it is here evidenced that neurons possess 
mechanisms that prevent deregulated cell cycles from reaching fruition. It is proposed that, like 
oncogenes, drivers of cell cycle re-entry such as Aβ cause cell cycle deregulation, checkpoint 
activation, and oncosuppressive cell death or senescence. Hence, the very methods used to induce 
cell cycle re-entry in neurons may have rendered the cell cycle machinery dysfunctional, which may 
be mistaken for neuron-specific cell cycle limitations. 
5.2. A postmitotic fallacy? 
It is here suggested that the contemporary understanding of the postmitotic status of neurons is 
the consequence of a logical fallacy, which itself stems from failing to differentiate between 
postmitotic as a state from postmitotic as a type of cell. If neurons are in a postmitotic state, there 
are no assumptions on whether neurons are mitotic or postmitotic cell types. As a state, the 
postmitotic status of otherwise mitotic neurons can be lost under pathological conditions, 
explaining why cell cycle re-entry is possible in neurons and why, as herein reported, the regulation 
of S, G2, and M-phase is shared with mitotic cells. Postmitotic as a state is reminiscent of 
quiescence. However, as opposed to quiescence, the postmitotic status would not be 
physiologically reversible. In contrast, if postmitotic is understood as a cell-type, cell cycle 
limitations are inherent to the very definition of a postmitotic neuron. This forces the fallacy where, 
ahead of any empirical evidence, cell cycle limitations are a logical imperative. That is, in as much 
as neurons are a postmitotic cell-type, they cannot relinquish the postmitotic status and still be 
neurons.  
It is here suggested that neurons are mitotic cells that are kept in a reversible postmitotic state, 
which is acquired during differentiation/maturation. In as much as neurons are arguably the 
paradigmatic postmitotic cell, it may very well be that postmitotic cell types do not exist altogether.  
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5.3. A mitotic neuron model. 
In the present studies, cell cycle re-entry has been induced with t1EK2, a fusion protein based on 
CycET1-Cdk2. CycE-Cdk2 is the holoenzyme that regulates canonical G1/S signaling in mitotic cells 
[19].  t1EK2 induced cell cycle re-entry evidences the Cdk2 phosphorylation program that drives 
canonical G1/S signaling is present in neurons. Hence, neurons and standard mitotic cells share the 
G1/S signaling backbone. Unlike t1EK2-expressing neurons, control neurons never undergo 
spontaneous cell cycle re-entry. There hence, the presence of a canonical G1/S signaling backbone 
in neurons is at odds with the lack of cell cycle activity in control neurons. This can be reconciled if 
neurons are mitotic cells that possess additional negative regulators of the cell cycle in G0 or G1. 
For ease of understanding, said negative regulators are herein termed “mitotic suppressors”. Unlike 
tumor suppressors, “mitotic suppressors” would exclusively prevent physiological cell cycle re-entry 
induced by mitogenic physiological drivers.    
Proteins with neuron-specific functions consistent with “mitotic suppression” are already 
described. As noted Cdk5 is an atypical kinase that binds Cyclin D and E isoforms [146,147,264–
266]. Unlike Cyclin D and Cyclin E binding to Cdk4/6 and Cdk2, respectively, binding of Cyclin D/E to 
Cdk5 does not result in kinase activity nor Rb phosphorylation. In as much virtually all Cyclin E 
expressed in neurons is sequestered by Cdk5 into inactive CycE-Cdk5 complexes [147], an evident 
putative “mitotic suppressor” candidate is Cdk5. This possibility is supported by transgenic models 
although, as a cautionary note, Cdk5 is also involved in differentiation [267].  Theoretically, 
physiological drivers of the cell cycle cannot push the cell cycle beyond late G1 because Cdk5 
sequestration of Cyclin E prevents the formation of CycE-Cdk2. If this sequestration is not 
downstream of physiological mitogenic regulation, the block on cell cycle re-entry is physiologically 
irreversible. However, strategies that overcome said sequestration (e.g. t1EK2) enable non-
physiological cell cycle re-entry, possibly because neurons are mitotic cells after all.    
Gathering the above, it is hypothesized that G0/G1 neuron-specific “mitotic suppressors” (Fig. 26a) 
prevent physiological cell cycle re-entry (Fig. 26b) by operating on top of the canonical G0/G1 
signaling backbone present in any mitotic cells. Without physiological cell cycle re-entry, 
physiological neuronal cell division cannot take place. This explains the postmitotic status of 
neurons as a state, not as a type of cell. If physiological re-entry is not possible, the alternatively is 
likely oncogenic-like supraphysiological stimulation. Oncogenes can induce neuronal cell cycle re-
entry (Fig. 26c), which results in the deregulation of the cell cycle machinery and, consequently, a 
pathological cell cycle (Fig. 26d). As in mitotic cells, this elicits cell cycle checkpoints (Fig. 26e) which 
in turn execute cell cycle arrest that can be conducive to cell death or senescence (Fig. 26f). Because 
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neurons are mitotic cells, they can enter the cell cycle and, also because they are mitotic cells, a 
pathological cell cycle results in cell death instead of cell division. Accordingly, neurodegeneration 
(Fig. 26g) during aberrant cell cycle re-entry may be a successful response to carcinogenesis (Fig. 
26h).  
Gathering the above, physiological neuronal cell division would never be reported if neurons are in 
a postmitotic state. Pathological cell division would never be reported after non-physiological cell 
cycle re-entry either if neurons are mitotic cells. However, in mitotic neurons in a postmitotic state, 
the postmitotic state could be experimentally reversed to induce physiological-like proliferation 
and replenish nervous tissue. Thus, controlled abrogation of “mitotic suppressors” (Fig. 26k) could 
render neurons responsive to physiological mitogens, enabling a physiological-like therapeutic 
neuronal cell cycle entry (Fig. 26l). Physiological-like therapeutic cell cycle re-entry (Fig. 26l) would 
not result in cell cycle deregulation and allow for neuroregeneration (Fig. 26m) without the risk of 
tumorigenesis.  
5.4. Future directions. 
The research of neurons as mitotic cells provides a new framework to understand aging and 
neurodegeneration. Neuronal cell cycle re-entry without cell division takes place at preclinical 
stages of AD [135] (but see  [268]). Although they do not immediately perish, these neurons are the 
most susceptible to cell death at clinical stages of AD [135]. Moreover, multinucleated neurons have 
been described in AD patients [229], indicating that neurons can enter and exit M-phase. Models 
of neuronal cell cycle re-entry largely resulted in immediate cell death [93]. This has precluded an 
understanding of how neurons in preclinical AD can attain viability after cell cycle re-entry or their 
susceptibility to cell death during clinical AD. However, work by our own laboratory has recently 
produced a model in which primary cortical neurons expressing LTAg undergo delayed cell death 
after cell cycle re-entry [262]. Moreover, the present work shows that after premature M-phase 
exit multinucleated neurons recover the AIS, a structural determinant of neuronal viability 
[227,228]. Therefore, in this model, viability can be assessed after cell cycle exit without cell 
division. The models developed in our laboratory may be instrumental to gain an unprecedented 
understanding of the mitotic biology underlying cell cycle deregulation in AD.  
The viable state that mitotic cells acquire upon premature cell cycle exit is senescence [2,269]. 
Senescent-like phenotypes have already been described in neurons in vivo and in vitro [71–77]. 
Hence, one possibility is that viable neurons in AD are in a senescent state. As noted, Aβ is reported 
to induce the re-activation of cell cycle program in neurons [125–130]. Hence, Aβ could be a 
senescence-inducing stressor. Along these lines, Aβ oligomers induce senescence in neuronal 
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stem/progenitor cells in both WT and AD mouse models [270]. Aβ peptide administration has been 
shown to induce senescence in WT astrocytes in vitro, which are increased in AD patients [271]. 
Finally, a senescent-like phenotype has been associated with neuron disease progression in tau 
transgenic mice models of AD [77]. Whether neurons can undergo bona fide senescence or not 
remains to be determined, but it is a possibility that can bestow a renewed understanding of AD as 
well as new therapeutic opportunities.   
t1EK2 and checkpoint abrogation used in the present work largely mimics carcinogenesis in breast 
cancer [154], and aneuploid neurons have been produced both after completing cytokinesis or after 
undergoing cytokinesis failure. Aneuploidy is a long-recognized feature of pre-cancerous/cancerous 
cells [272]. Still, reports of neuronal contribution to cancer are only sparse and appear to require 
prior dedifferentiation [88]. That is, neurons do not significantly contribute to tumor formation. If 
the present in vitro results are applicable in vivo, neuronal resistance to cancer could not be 
explained by mitotic incompetence. If, as is here suggested, neurons are mitotic cells in a 
postmitotic state, it is the postmitotic state that likely protects neurons from tumor formation. 
Much like the senescence state prevents tumorigenesis, the postmitotic status of neurons may be 
exploited to design new treatments for cancer. Namely induce the postmitotic state in cancerous 
cells. For example, the candidate “mitotic suppressor” Cdk5 can be used to template interfering 
peptides to emulate the sequestration of Cyclin E away from Cdk2 in tumor cells.  
Finally, evidence is provided that WT mature neurons at post-synaptogenesis stages possess 
functional cell cycle machinery and can undergo cell division. This indicates that, in addition to NSC 
and iPSC, differentiated neuron proliferation might be a new avenue for neuron replenishment 
therapies. This approach would overcome important caveats inherent to NPC and iPSC. First, 
theoretically, differentiated neuron proliferation does not require re-differentiation into the 
desired neuronal types, including excitatory pyramidal cells. Second, neurons are already present 
throughout the nervous system, so the need for ex-vivo culture and autologous transplantation 
would be foregone. Clearly, the carcinogenic model described here cannot be used to bestow 
neuronal proliferation (Fig. 26b), as it would more likely result in reduced rates of proliferation 
because it would mostly result in cell death and senescence. Along these lines, despite 
cardiomyocytes have been shown to proliferate, approaches to stimulate cardiomyocytes 
proliferation and achieve heart muscle regeneration by oncogenic-like mechanisms (e.g. neuregulin 
overexpression) have had limited success [273]. More importantly, cell division would be 
potentially cancerous (Fig. 26j) and therefore high rates of proliferation, if achieved, would result 
in carcinogenesis (Fig. 26h), not neuron replenishment. As mentioned above, controlled abrogation 
of mitotic suppression (Fig. 26c) can potentially bestow neuron replenishment (Fig. 26m). Future 
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work will have to determine whether neuronal cell division can afford therapeutic 
neuroregeneration. For now, the present work establishes it is no longer impossible “for the science 
of the future to change, if possible, this harsh decree”. 
 
 
Figure 26. A mitotic neuron model. A Neurons possess a standard G1/S signaling backbone with 
added “mitotic suppressors” (a), which make mitotic neurons unable to respond to physiological 
mitogenic drivers (i.e. growth factors) and undergo a physiological cell cycle (b). B This 
postmitotic state can be hijacked by oncogenic-like t1EK2 (c). If neuronal cell cycle re-entry 
cannot be physiologically induced, mitotic activity in neurons can only be associated with a 
pathological cell cycle deregulation (d). In response to cell cycle deregulation, as mitotic cells, 
neurons possess cell cycle checkpoints to arrest the cell cycle and block neuronal cell division 
(e). Hence, cell cycle re-entry in neurons is largely followed by cell cycle arrest, cell death and or 
senescence (f) but not cell division. This entails that neurodegeneration (g) is a consequence of 
efficient cancer suppression (h). However, checkpoint abrogation (i) results in cell cycle 
progression that can result in pathological neuronal cell division (j). C, If the mechanisms that 
block physiological cell cycle re-entry can be temporarily reversed (k), it may be possible to 
induce a physiological-like therapeutic cell cycle (l) to afford neuroregeneration (m). 
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6. Conclusions  
 
1. Control primary neurons do not spontaneously re-enter the cell cycle. 
2. The physiological block of cell cycle re-entry is overcome by t1EK2 and EK2. 
3. Cell cycle re-entry is driven in primary neurons by the same Cdk2 phosphorylation program that 
drives the G1/S transition in mitotic cells.  
4. Cell cycle checkpoint signaling regulation in primary neurons is consistent with the presence of 
G1/S, G2, S-M checkpoints and the SAC.  
5. Primary neurons have functional G1, S, G2, and M-phase machinery and can undergo cell 
division. 
6. In the absence of final abscission, primary neurons can viably exit M-phase.  
 
6. Conclusiones 
1. En condiciones de control, las neuronas primarias no entran en ciclo de forma espontánea. 
2. El bloqueo fisiológico a la re-entrada en ciclo es superado por t1EK2 y EK2. 
3. La entrada en ciclo de neuronas primarias depende del mismo programa de fosforilación 
mediado por Cdk2 que regula la transición G1/S en células mitóticas.  
4. La regulación de puntos de control del ciclo celular en neuronas primarias es consistente con la 
presencia de los puntos de control G1/S, G2, S-M y el SAC. 
5. Las neuronas primarias tienen maquinaria de ciclo funcional en las fases G1/S/G2/M y pueden 
llevar a cabo la división celular. 
6. Cuando no llegan a completar la citocinesis, las neuronas primarias pueden salir de forma viable 
de la fase M.  
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8. Annex 
8.1. Annex 1. t1EK2-pcDNA3 
 
Gacggatcgggagatctcccgatcccctatggtcgactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctgc
ttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgct
tagggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattac
ggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgc
ccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggactatttacggtaaactg
cccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgccca
gtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaa
tgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgg
gactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctctc
tggctaactagagaacccactgcttactggcttatcgaaattaatacgactcactatagggagacccaAGCTTGGTACCGAGCTC
GGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCCCACATGGACTATAAGGACGATGATGACAAA
GATCCAGATGAAGAAATGGCCAAAATCGACAGGACGGCGAGGGACCAGTGTGGGAGCCAGCCTTGGG
ACAATAATGCAGTCTGTGCAGACCCCTGCTCCCTGATCCCCACACCTGACAAAGAAGATGATGACCGGG
TTTACCCAAACTCAACGTGCAAGCCTCGGATTATTGCACCATCCAGAGGCTCCCCGCTGCCTGTACTGAG
CTGGGCAAATAGAGAGGAAGTCTGGAAAATCATGTTAAACAAGGAAAAGACATACTTAAGGGATCAGC
ACTTTCTTGAGCAACACCCTCTTCTGCAGCCAAAAATGCGAGCAATTCTTCTGGATTGGTTAATGGAGGT
GTGTGAAGTCTATAAACTTCACAGGGAGACCTTTTACTTGGCACAAGATTTCTTTGACCGGTATATGGCG
ACACAAGAAAATGTTGTAAAAACTCTTTTACAGCTTATTGGGATTTCATCTTTATTTATTGCAGCCAAACT
TGAGGAAATCTATCCTCCAAAGTTGCACCAGTTTGCGTATGTGACAGATGGAGCTTGTTCAGGAGATGA
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AATTCTCACCATGGAATTAATGATTATGAAGGCCCTTAAGTGGCGTTTAAGTCCCCTGACTATTGTGTCC
TGGCTGAATGTATACATGCAGGTTGCATATCTAAATGACTTACATGAAGTGCTACTGCCGCAGTATCCCC
AGCAAATCTTTATACAGATTGCAGAGCTGTTGGATCTCTGTGTCCTGGATGTTGACTGCCTTGAATTTCCT
TATGGTATACTTGCTGCTTCGGCCTTGTATCATTTCTCGTCATCTGAATTGATGCAAAAGGTTTCAGGGTA
TCAGTGGTGCGACATAGAGAACTGTGTCAAGTGGATGGTTCCATTTGCCATGGTTATAAGGGAGACGG
GGAGCTCAAAACTGAAGCACTTCAGGGGCGTCGCTGATGAAGATGCACACAACATACAGACCCACAGA
GACAGCTTGGATTTGCTGGACAAAGCCCGAGCAAAGAAAGCCATGTTGTCTGAACAAAATAGGGCTTCT
CCTCTCCCCAGTGGGCTCCTCACCCCGCCACAGAGCGGTAAGAAGCAGAGCAGCGGGCCGGAAATGGC
GGGTGGTGGAGGTTCTGGAGGTGGAGGATCCGGTGGTGGAGGTGAGAACTTCCAAAAGGTGGAAAA
GATCGGAGAGGGCACGTACGGAGTTGTGTACAAAGCCAGAAACAAGTTGACGGGAGAGGTGGTGGCG
CTTAAGAAAATCCGCCTGGACACTGAGACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTG
CTTAAGGAGCTTAACCATCCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACC
TGGTTTTTGAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCTCTT
CCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCTCATCGGGTCCTCCA
CCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCCATCAAGCTAGCAGACTTTGGACT
AGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACCCATGAGGTGGTGACCCTGTGGTACCGAGCTCCT
GAAATCCTCCTGGGCTGCAAATATTATTCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTG
AGATGGTGACTCGCCGGGCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGAC
TCTGGGGACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTCCC
CAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGGAGCTTGTTATC
GCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCCCTGGCTCACCCTTTCTTCCAG
GATGTGACCAAGCCAGTACCCCATCTTCGACTCCACCACCACCACCACCACTGAAACTGATAACTTCGTA
TAATGTATGCTATACGAAGTTATTctagagggccctattctatagtgtcacctaaatgctagagctcgctgatcagcctcgact
gtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaa
atgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgggaa
gacaatagcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgc
gccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctccttt
cgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcggggcatccctttagggttccgatttagtgctttac
ggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttgga
gtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgggg
atttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaa
gtccccaggctccccaggcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctcccca
gcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgccc
agttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcctctgcctctgagctattccagaagtag
tgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagcttgtatatccattttcggatctgatcaagagacaggatgag
gatcgtttcgcatgattgaacaagatggattgcacgcaggttctccggccgcttgggtggagaggctattcggctatgactgggcacaac
agacaatcggctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagaccgacctgtccggtgccct
gaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgctcgacgttgtcactgaag
cgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcatctcaccttgctcctgccgagaaagtatccatcatgg
ctgatgcaatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcgaaacatcgcatcgagcgagcacgtactc
ggatggaagccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgcgccagccgaactgttcgccaggctcaaggcg
cgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgccgaatatcatggtggaaaatggccgcttttctggattca
tcgactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggctacccgtgatattgctgaagagcttggcggcgaatggg
ctgaccgcttcctcgtgctttacggtatcgccgctcccgattcgcagcgcatcgccttctatcgccttcttgacgagttcttctgagcgggac
tctggggttcgaaatgaccgaccaagcgacgcccaacctgccatcacgagatttcgattccaccgccgccttctatgaaaggttgggcttc
ggaatcgttttccgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagc
ttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcat
caatgtatcttatcatgtctgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccg
ctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttg
cgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtatt
gggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatac
ggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcg
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ttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggacta
taaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctccct
tcgggaagcgtggcgctttctcaatgctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaacc
ccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagcc
actggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaaggac
agtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagc
ggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctca
gtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtttt
aaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcg
ttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcga
gacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgc
ctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggca
tcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaa
aaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattc
tcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagtt
gctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaa
aactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcg
tttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcct
ttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttc
cgcgcacatttccccgaaaagtgccacctgacgtc 
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8.2 Annex 2. EK2-pcDNA3 
 
gacggatcgggagatctcccgatcccctatggtcgactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctgct
tgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt
agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattac
ggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgc
ccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggactatttacggtaaactg
cccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgccca
gtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaa
tgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgg
gactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctctc
tggctaactagagaacccactgcttactggcttatcgaaattaatacgactcactatagggagacccaAGCTTGGTACCGAGCTC
GGATCCACTAGTAACGGCCGCCAGTGTGCTGGaattcccaccatggactataaggacgatgatgacaaaaaggaggac
ggcggcgcggagttctcggctcgctccaggaagaggaaggcaaacgtgaccgtttttttgcaggatccagatgaagaaatggccaaaat
cgacaggacggcgagggaccagtgtgggagccagccttgggacaataatgcagtctgtgcagacccctgctccctgatccccacacctg
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acaaagaagatgatgaccgggtttacccaaactcaacgtgcaagcctcggattattgcaccatccagaggctccccgctgcctgtactga
gctgggcaaatagagaggaagtctggaaaatcatgttaaacaaggaaaagacatacttaagggatcagcactttcttgagcaacaccc
tcttctgcagccaaaaatgcgagcaattcttctggattggttaatggaggtgtgtgaagtctataaacttcacagggagaccttttacttgg
cacaagatttctttgaCCGGTATATGGCGACACAAGAAAATGTTGTAAAAACTCTTTTACAGCTTATTGGGATT
TCATCTTTATTTATTGCAGCCAAACTTGAGGAAATCTATCCTCCAAAGTTGCACCAGTTTGCGTATGTGAC
AGATGGAGCTTGTTCAGGAGATGAAATTCTCACCATGGAATTAATGATTATGAAGGCCCTTAAGTGGCG
TTTAAGTCCCCTGACTATTGTGTCCTGGCTGAATGTATACATGCAGGTTGCATATCTAAATGACTTACATG
AAGTGCTACTGCCGCAGTATCCCCAGCAAATCTTTATACAGATTGCAGAGCTGTTGGATCTCTGTGTCCT
GGATGTTGACTGCCTTGAATTTCCTTATGGTATACTTGCTGCTTCGGCCTTGTATCATTTCTCGTCATCTG
AATTGATGCAAAAGGTTTCAGGGTATCAGTGGTGCGACATAGAGAACTGTGTCAAGTGGATGGTTCCAT
TTGCCATGGTTATAAGGGAGACGGGGAGCTCAAAACTGAAGCACTTCAGGGGCGTCGCTGATGAAGAT
GCACACAACATACAGACCCACAGAGACAGCTTGGATTTGCTGGACAAAGCCCGAGCAAAGAAAGCCAT
GTTGTCTGAACAAAATAGGGCTTCTCCTCTCCCCAGTGGGCTCCTCACCCCGCCACAGAGCGGTAAGAA
GCAGAGCAGCGGGCCGGAAATGGCGGGTGGTGGAGGTTCTGGAGGTGGAGGATCCGGTGGTGGAGG
TGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAAGCCAGAAAC
AAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAGACTGAGGGTGTGCCCA
GTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCATCCTAATATTGTCAAGCTGCTGGATGT
CATTCACACAGAAAATAAACTCTACCTGGTTTTTGAATTTCTGCACCAAGATCTCAAGAAATTCATGGAT
GCCTCTGCTCTCACTGGCATTCCTCTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGC
TTTCTGCCATTCTCATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGG
GCCATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACCCATGAGG
TGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTATTCCACAGCTGTGGACAT
CTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGGGCCCTATTCCCTGGAGATTCTGAGAT
TGACCAGCTCTTCCGGATCTTTCGGACTCTGGGGACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTC
TATGCCTGATTACAAGCCAAGTTTCCCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTG
GATGAAGATGGACGGAGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAG
GCAGCCCTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCCACCACCACC
ACCACCACTGAAACTGATAACTTCGTATAATGTATGCTATACGAAGTTATTctagagggccctattctatagtgtca
cctaaatgctagagctcgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctg
gaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggt
ggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaag
aaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccg
ctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcg
gggcatccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcg
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ccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatc
tcggtctattcttttgatttataagggattttggggatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattaa
ttctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccaggcaggcagaagtatgcaaagcatgcatctcaattagtca
gcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgcc
cctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccga
ggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagcttgtatat
ccattttcggatctgatcaagagacaggatgaggatcgtttcgcatgattgaacaagatggattgcacgcaggttctccggccgcttgggt
ggagaggctattcggctatgactgggcacaacagacaatcggctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccgg
ttctttttgtcaagaccgacctgtccggtgccctgaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgacgggcgttc
cttgcgcagctgtgctcgacgttgtcactgaagcgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcatctc
accttgctcctgccgagaaagtatccatcatggctgatgcaatgcggcggctgcatacgcttgatccggctacctgcccattcgac 
caccaagcgaaacatcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaagagcatcagg
ggctcgcgccagccgaactgttcgccaggctcaaggcgcgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgc
cgaatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggc
tacccgtgatattgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccgattcgcagcgcatc
gccttctatcgccttcttgacgagttcttctgagcgggactctggggttcgaaatgaccgaccaagcgacgcccaacctgccatcacgaga
tttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatgatcctccagcgcggggatctca
tgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagc
atttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcgacctctagctagagcttggcgt
aatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctg
gggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaat
gaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggct
gcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaa
aggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatc
gacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttc
cgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcaatgctcacgctgtaggtatctcagttcgg
tgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtcc
aacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagt
tcttgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagt
tggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatc
tcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaa
aggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatg
cttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacggg
agggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagcc
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ggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcg
ccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcc
caacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg
ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtact
caaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcaga
actttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaaccca
ctcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagg
gaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcgga
tacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtc 
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